Sleep quality data collection and evaluation

- Cardiac Pacemakers, Inc.

A sleep quality assessment approach involves collecting data based on detected physiological or non-physiological patient conditions. At least one of detecting patient conditions and collecting data is performed using an implantable device. Sleep quality may be evaluated using the collected data by an implantable or patient-external sleep quality processor. One approach to sleep quality evaluation involves computing one or more summary metrics based on occurrences of movement disorders or breathing disorders during sleep.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
RELATED PATENT DOCUMENT

This application is a division of U.S. patent application Ser. No. 10/642,998 filed on Aug. 18, 2003, to issue on Aug. 23, 2011 as U.S. Pat. No. 8,002,553 which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates generally to collecting and evaluating information related to sleep quality.

BACKGROUND OF THE INVENTION

Sleep is generally beneficial and restorative to a patient, exerting great influence on the quality of life. The human sleep/wake cycle generally conforms to a circadian rhythm that is regulated by a biological clock. Regular periods of sleep enable the body and mind to rejuvenate and rebuild. The body may perform various tasks during sleep, such as organizing long term memory, integrating new information, and renewing tissue and other body structures.

Normal sleep is characterized by a general decrease in metabolic rate, body temperature, blood pressure, breathing rate, heart rate, cardiac output, sympathetic nervous activity, and other physiological functions. However, studies have shown that the brain's activity does not decrease significantly during sleep. Normally a patient alternates between rapid eye movement (REM) and non-REM (NREM) sleep in approximately 90 minute cycles throughout a sleep period. A typical eight hour sleep period may be characterized in terms of a five-step sleep cycle identifiable through EEG brain wave activity.

Non-REM sleep includes four sleep states or stages that range from light dozing to deep sleep. Throughout NREM sleep, muscle activity is still functional, breathing is low, and brain activity is minimal. Approximately 85% of the sleep cycle is spent in NREM sleep. Stage 1 NREM sleep may be considered a transition stage between wakefulness and sleep. As sleep progresses to stage 2 NREM sleep, eye movements become less frequent and brain waves increase in amplitude and decrease in frequency. As sleep becomes progressively deeper, the patient becomes more difficult to arouse. Stage 3 sleep is characterized by 20 to 40% slow brain wave (delta) sleep as detected by an electroencephalogram (EEG). Sleep stages 3 and 4 are considered to be the most restful sleep stages.

REM sleep is associated with more prevalent dreaming, rapid eye movements, muscle paralysis, and irregular breathing, body temperature, heart rate and blood pressure. Brain wave activity during REM sleep is similar to brain wave activity during a state of wakefulness. There are typically 4-6 REM periods per night, with increasing duration and intensity toward morning. While dreams can occur during either REM or NREM sleep, the nature of the dreams varies depending on the type of sleep. REM sleep dreams tend to be more vivid and emotionally intense than NREM sleep dreams. Furthermore, autonomic nervous system activity is dramatically altered when REM sleep is initiated.

Lack of sleep and/or decreased sleep quality may be have a number of causal factors including, e.g., nerve or muscle disorders, respiratory disturbances, and emotional conditions, such as depression and anxiety. Chronic, long-term sleep-related disorders e.g., chronic insomnia, sleep-disordered breathing, and sleep movement disorders, including restless leg syndrome (RLS), periodic limb movement disorder (PLMD) and bruxism, may significantly affect a patient's sleep quality and quality of life.

Movement disorders such as restless leg syndrome (RLS), and a related condition, denoted periodic limb movement disorder (PLMD), are emerging as one of the more common sleep disorders, especially among older patients. Restless leg syndrome is a disorder causing unpleasant crawling, prickling, or tingling sensations in the legs and feet and an urge to move them for relief. RLS leads to constant leg movement during the day and insomnia or fragmented sleep at night. Severe RLS is most common in elderly people, although symptoms may develop at any age. In some cases, it may be linked to other conditions such as anemia, pregnancy, or diabetes.

Many RLS patients also have periodic limb movement disorder (PLMD), a disorder that causes repetitive jerking movements of the limbs, especially the legs. These movements occur approximately every 20 to 40 seconds and cause repeated arousals and severely fragmented sleep.

A significant percentage of patients between 30 and 60 years experience some symptoms of disordered breathing, primarily during periods of sleep. Sleep disordered breathing is associated with excessive daytime sleepiness, systemic hypertension, increased risk of stroke, angina and myocardial infarction. Disturbed respiration can be particularly serious for patients concurrently suffering from cardiovascular deficiencies. Disordered breathing is particularly prevalent among congestive heart failure patients, and may contribute to the progression of heart failure.

Sleep apnea is a fairly common breathing disorder characterized by periods of interrupted breathing experienced during sleep. Sleep apnea is typically classified based on its etiology. One type of sleep apnea, denoted obstructive sleep apnea, occurs when the patient's airway is obstructed by the collapse of soft tissue in the rear of the throat. Central sleep apnea is caused by a derangement of the central nervous system control of respiration. The patient ceases to breathe when control signals from the brain to the respiratory muscles are absent or interrupted. Mixed apnea is a combination of the central and obstructive apnea types. Regardless of the type of apnea, people experiencing an apnea event stop breathing for a period of time. The cessation of breathing may occur repeatedly during sleep, sometimes hundreds of times a night and occasionally for a minute or longer.

In addition to apnea, other types of disordered respiration have been identified, including, for example, hypopnea (shallow breathing), dyspnea (labored breathing), hyperpnea (deep breathing), and tachypnea (rapid breathing). Combinations of the disordered respiratory events described above have also been observed. For example, Cheyne-Stokes respiration (CSR) is associated with rhythmic increases and decreases in tidal volume caused by alternating periods of hyperpnea followed by apnea and/or hypopnea. The breathing interruptions of CSR may be associated with central apnea, or may be obstructive in nature. CSR is frequently observed in patients with congestive heart failure (CHF) and is associated with an increased risk of accelerated CHF progression.

An adequate duration and quality of sleep is required to maintain physiological homeostasis. Untreated, sleep disturbances may have a number of adverse health and quality of life consequences ranging from high blood pressure and other cardiovascular disorders to cognitive impairment, headaches, degradation of social and work-related activities, and increased risk of automobile and other accidents.

Various modifications and additions can be made to the preferred embodiments discussed hereinabove without departing from the scope of the present invention. Accordingly, the scope of the present invention should not be limited by the particular embodiments described above, but should be defined only by the claims set forth below and equivalents thereof.

SUMMARY OF THE INVENTION

Various embodiments of present invention involve methods and systems for collecting sleep quality data and evaluating the sleep quality of a patient.

An embodiment of the invention involves a method for collecting sleep quality data. The method includes detecting physiological and non-physiological conditions associated with the sleep quality of a patient and collecting sleep quality data based on the detected conditions. Collecting the sleep quality data is performed at least in part implantably.

Another embodiment of the invention involves a method for evaluating sleep quality. In accordance with this method, one or more metrics associated with sleep are determined. One or more metrics associated with events that disrupt sleep are determined. A composite sleep quality metric is determined using the one or more metrics associated with sleep and the one or more metrics associated with events that disrupt sleep.

In yet another embodiment of the invention, a method for evaluating sleep quality includes detecting physiological and non-physiological conditions associated with the sleep quality of a patient and collecting sleep quality data based on the detected conditions. The sleep quality of the patient is evaluated using the collected data. At least one of collecting the sleep quality data and evaluating the sleep quality of the patient is performed at least in part implantably.

Another embodiment of the invention involves a method for evaluating sleep quality. One or more conditions associated with sleep quality of a patient are detected during a period of wakefulness. Sleep quality data is collected based on the detected conditions. The patient's sleep quality is evaluated using the collected sleep quality data. At least one of collecting the data and evaluating the sleep quality is performed at least in part implantably.

A further embodiment of the invention involves a medical device including a detector system configured to detect physiological and non-physiological conditions associated with sleep quality and a data collection system for collecting sleep quality data based on the detected conditions. The data collection system includes an implantable component.

Yet another embodiment of the invention relates to a medical device configured to evaluate sleep quality. The medical device includes a detector system configured to detect physiological and non-physiological conditions associated with the sleep quality of a patient. A sleep quality processor, coupled to the detection system, is configured to determine metrics based on the detected conditions. The metrics include one or more metrics associated with sleep, one or more metrics associated with events that disrupt sleep, and at least one composite sleep quality metric based on the one or more metrics associated with sleep and the one or more metrics associated with events that disrupt sleep.

In another embodiment of the invention, a medical device for assessing sleep quality includes a detector unit configured to detect physiological and non-physiological conditions associated with sleep quality and a sleep quality data collection unit configured to collect sleep quality data based on the detected conditions. A data analysis unit coupled to the data collection unit evaluates sleep quality based on the collected sleep quality data. At least one of the data collection unit and the data analysis unit includes an implantable component.

A further embodiment of the invention involves a system for collecting sleep quality data. The system includes means for detecting physiological and non-physiological conditions associated with sleep quality and means for collecting sleep quality data based on the detected conditions. The means for collecting the sleep quality data includes an implantable component.

In yet another embodiment of the invention, a system for assessing sleep quality includes means for determining one or more metrics associated with sleep and means for determining one or more metrics associated with events that disrupt sleep. The system further includes means for determining a composite sleep quality metric as a function of the metrics associated with sleep and the metrics associated with events that disrupt sleep.

Another embodiment of the invention involves a system for evaluating sleep quality. The system includes means for detecting physiological and non-physiological conditions associated with sleep quality and means for collecting sleep quality data based on the detected conditions. The system includes means for evaluating the sleep quality of the patient based on the collected sleep quality data. At least one of the means for collecting the sleep quality data and the means for evaluating the sleep quality comprise an implantable component.

A further embodiment involves a system for evaluating the sleep quality of a patient. The system includes means for detecting one or more patient conditions associated with sleep quality during a period of wakefulness and means for collecting sleep quality data based on the detected conditions. The system further includes means for evaluating the sleep quality of the patient using the collected sleep quality data. At least one of the means for collecting the sleep quality data and means for evaluating the sleep quality include an implantable component.

The above summary of the present invention is not intended to describe each embodiment or every implementation of the present invention. Advantages and attainments, together with a more complete understanding of the invention, will become apparent and appreciated by referring to the following detailed description and claims taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flow chart illustrating a method of collecting sleep quality data in accordance with embodiments of the invention;

FIG. 2 illustrates a block diagram of a sleep quality data system in accordance with embodiments of the invention;

FIG. 3 is a system block diagram illustrating a sleep quality data system incorporated within a cardiac rhythm management system in accordance with embodiments of the invention;

FIG. 4 is a block diagram of a sleep detection unit that may be used as part of a sleep quality data system according to embodiments of the invention;

FIG. 5 is a flow chart illustrating a sleep detection method according to embodiments of the invention;

FIG. 6 is a flow chart illustrating a method for detecting sleep as a part of a sleep quality data collection approach according to embodiments of the invention;

FIG. 7 is a graph of a patient's activity condition as indicated by an accelerometer signal;

FIG. 8 is a graph of a patient's heart rate;

FIG. 9 is a graph of a patient's minute ventilation (MV) condition;

FIG. 10 illustrates adjustment of a sleep threshold in accordance with embodiments of the invention;

FIG. 11 illustrates a normal respiration pattern as represented by a transthoracic impedance sensor signal;

FIG. 12 illustrates respiration intervals used for disordered breathing detection according to embodiments of the invention;

FIG. 13 illustrates detection of sleep apnea and severe sleep apnea according to embodiments of the invention;

FIGS. 14A-B are graphs of tidal volume derived from transthoracic impedance measurements according to embodiments of the invention;

FIG. 15 is a flow chart illustrating a method of apnea and hypopnea detection according to embodiments of the invention;

FIG. 16 is a graph illustrating a breathing interval according to embodiments of the invention;

FIG. 17 is a graph illustrating a hypopnea detection approach in accordance with embodiments of the invention;

FIGS. 18A-B are charts illustrating nomenclature for individual disordered breathing events and combinations of disordered breathing events, respectively;

FIGS. 18C-G are graphs illustrating disordered breathing events comprising a combination of apnea and hypopnea respiration cycles;

FIG. 19 is a flow chart of a method for detecting disordered breathing by classifying breathing patterns in accordance with embodiments of the invention; and

FIG. 20 illustrates a patient instrumented with components of a sleep quality data system according to embodiments of the invention.

While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail below. It is to be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.

DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS

In the following description of the illustrated embodiments, references are made to the accompanying drawings which form a part hereof, and in which are shown, by way of illustration, various embodiments by which the invention may be practiced. It is to be understood that other embodiments may be utilized. Structural and functional changes may be made without departing from the scope of the present invention.

Sleep quality assessments depend upon acquiring sleep-related data, including the patient's typical sleep patterns and the physiological, environmental, contextual, emotional, and other conditions affecting the patient during sleep. Diagnosis of sleep disorders and assessment of sleep quality often involves the use of a polysomnographic sleep study at a dedicated sleep facility. However, such studies are costly, inconvenient to the patient, and may not accurately represent the patient's typical sleep behavior. In a polysomnographic sleep study, the patient is instrumented for data acquisition and observed by trained personnel. Sleep assessment in a laboratory setting presents a number of obstacles in acquiring an accurate picture of a patient's typical sleep patterns. For example, spending a night in a sleep laboratory typically causes a patient to experience a condition known as “first night syndrome,” involving disrupted sleep during the first few nights in an unfamiliar location. In addition, sleeping while instrumented and observed may not result in a realistic perspective of the patient's normal sleep patterns.

Further, polysomnographic sleep studies provide an incomplete data set for the analysis of some sleep disorders, including, for example, sleep disordered breathing. A number of physiological conditions associated with sleep disordered breathing are detectable during periods of wakefulness, e.g., decreased heart rate variability, elevated sympathetic nerve activity, norepinephrine concentration, and increased blood pressure variability. Collection of data during periods of sleep and/or during periods of wakefulness may provide a more complete picture of the patient's sleep quality.

Various aspects of sleep quality, including number and severity of arousals, sleep disordered breathing episodes, nocturnal limb movements, and cardiac, respiratory, muscle, and nervous system functioning may provide important information for diagnosis and/or therapy delivery. An initial step to sleep quality evaluation is an accurate and reliable method for discriminating between periods of sleep and periods of wakefulness. Further, acquiring data regarding the patient's sleep states or stages, including sleep onset, termination, REM, and NREM sleep states may be used in connection sleep quality assessment. For example, the most restful sleep occurs during stages 3 and 4 NREM sleep. One indicator of sleep quality is the percentage of time a patient spends in these sleep stages. Knowledge of the patient's sleep patterns may be used to diagnose sleep disorders and/or adjust patient therapy, including, e.g., cardiac or respiratory therapy. Trending disordered breathing episodes, arousal episodes, and other sleep quality aspects may be helpful in determining and maintaining appropriate therapies for patients suffering from disorders ranging from snoring to chronic heart failure.

The present invention involves methods and systems for acquiring sleep quality data using one or more implantable components. As illustrated in FIG. 1, methods of the invention involve detecting conditions associated with the sleep quality of the patient 110, including physiological and non-physiological conditions. Data related to the patient's sleep quality is collected based on the detected conditions 120. Detection of patient conditions related to sleep quality may occur during periods of wakefulness and/or during periods of sleep. Either detecting the conditions associated with sleep quality, or collecting the sleep quality data, or both, is performed using a device having a component that is at least in part implantable.

A representative set of the conditions associated with sleep quality is listed in Table 1. Patient conditions used to evaluate sleep quality may include, for example, both physiological and non-physiological (i.e., contextual) conditions. Physiological conditions associated with sleep quality may be further organized, for example, into conditions of the cardiovascular, respiratory, muscle, and nervous systems, and conditions relating to the patient's blood chemistry.

Contextual conditions may be further subdivided into environmental conditions, body-related conditions and historical/background conditions. Environmental conditions may be broadly defined to include the environmental surroundings affecting the patient, such as ambient light, temperature, humidity, air pollution, noise, and barometric pressure. Body-related conditions may include, for example, patient location, posture, and altitude. Contextual conditions relevant to sleep quality may also include historical or background conditions. For example, a patient's medical/psychological history, gender, age, weight, body mass index, neck size, drug use, and emotional state may be detected and used in connection with sleep quality evaluation and sleep disorder diagnosis. Methods and systems for detecting contextual conditions are described in commonly owned U.S. Pat. No. 7,400,928, which is incorporated herein by reference.

TABLE 1 Sensor type or Detection Condition Type Condition method Physiological Cardiovascular Heart rate EGM, ECG System Heart rate variability QT interval Ventricular filling pressure Intracardiac pressure sensor Blood pressure Blood pressure sensor Respiratory System Snoring Accelerometer Microphone Respiration pattern Transthoracic impedance (Tidal volume Minute sensor (AC) ventilation Respiratory rate) Patency of upper airway Intrathoracic impedance sensor Pulmonary congestion Transthoracic impedance sensor (DC) Nervous System Sympathetic nerve activity Muscle sympathetic nerve Activity sensor Brain activity EEG Blood Chemistry CO2 saturation Blood analysis O2 saturation Blood alcohol content Adrenalin Brain Natriuretic Peptide (BNP) C-Reactive Protein Drug/Medication/Tobacco use Muscle System Muscle atonia EMG Eye movement EOG Patient activity Accelerometer, MV, etc. Limb movements Accelerometer Jaw movements Non- Environmental Ambient temperature Thermometer physiological Humidity Hygrometer Pollution Air quality website Time Clock Barometric pressure Barometer Ambient noise Microphone Ambient light Photodetector Body-related Posture Posture sensor Altitude Altimeter Location GPS, proximity sensor Proximity to bed Proximity to bed sensor Historical/Background Historical sleep time Patient input, previously detected sleep onset times Medical history Patient input device Age Recent exercise Weight Gender Body mass index Neck size Emotional state Psychological history Daytime sleepiness Patient perception of sleep quality Drug, alcohol, nicotine use

Each of the conditions listed in Table 1 may serve a variety of purposes in evaluating sleep quality. For example, a subset of the conditions may be used to detect whether the patient is asleep and to track the various stages of sleep and arousal incidents. Another subset of the conditions may be used to detect disordered breathing episodes. Yet another subset may be used to detect abnormal limb movements. In one implementation, some or all of the listed conditions may be collected over a relatively long period of time and used to analyze long term sleep quality trends. Trending may be used in connection with an overall assessment of sleep quality and diagnosis and treatment of sleep-disordered breathing, movement disorders, and/or other sleep disorders.

In one implementation, sleep quality analysis may be used within the structure of an advanced patient management system. In this implementation, an advanced patient management system having sleep quality analysis capability allows a physician to remotely and automatically monitor cardiac and respiratory functions, as well as other patient conditions, including information related to sleep quality. In one example, an implantable cardiac rhythm management system, such as a cardiac monitor, pacemaker, defibrillator, or resynchronization device, may be equipped with various telecommunications and information technologies to enable real-time data collection, diagnosis, and treatment of the patient. Systems and methods involving advanced patient management techniques are described in U.S. Pat. Nos. 6,336,903, 6,312,378, 6,270,457, and 6,398,728 which are incorporated herein by reference in their respective entireties.

Table 2 provides examples of how some physiological and non-physiological conditions may be used in connection with sleep quality assessment.

TABLE 2 Examples of how condition is used in sleep quality Condition Type Condition assessment Physiological Heart rate Decrease in heart rate may indicate disordered breathing episode. Decrease in heart rate may indicate the patient is asleep. Heart rate variability May be used to determine sleep state. Changes in heart rate variability, detected during periods of sleep or wakefulness, may indicate that the patient suffers from sleep disordered breathing. QT interval May be used to detect sleep apnea. Ventricular filling pressure May be used to identify/predict pulmonary congestion associated with respiratory disturbance. Blood pressure Variation in blood pressure is associated with apnea. Snoring Associated with a higher incidence of obstructive sleep apnea and may be used to detect disordered breathing. Respiration pattern May be used to detect disordered breathing episodes. May be used to determine the type of disordered breathing. May be used to detect sleep. Patency of upper airway Related to obstructive sleep apnea and may be used to detect episodes of obstructive sleep apnea. Pulmonary congestion Associated with respiratory disturbances. Sympathetic nerve Apnea termination is associated with a spike in SNA. activity (SNA) SNA activity may be elevated during periods of wakefulness if the patient experiences sleep disordered breathing. Electroencephalogram May be used to determine sleep stages, including REM (EEG) and NREM sleep stages CO2 saturation Low CO2 levels may indicate initiation of central apnea. O2 saturation O2 desaturation occurs during severe apnea/hypopnea episodes. Blood alcohol content Alcohol tends to increase the incidence of snoring & obstructive apnea. Adrenalin End of apnea associated with a spike in blood adrenaline. Brain Natriuretic Peptide A marker of heart failure status, which is associated with (BNP) Cheyne-Stokes Respiration. C-Reactive Protein A measure of inflammation that may be related to apnea. Drug/Medication/Tobacco These substances may affect incidence of both central use & obstructive apnea. Muscle atonia Muscle atonia may be used in connection with detection of REM and non-REM sleep. Eye movement Eye movement may be used in connection with detection of REM and non-REM sleep. Activity May be used to detect sleep and patient well being. Limb movements May be used to detect abnormal limb movements during sleep. Non- Ambient Temperature Ambient temperature may predispose the patient to physiological episodes of disordered breathing during sleep. Humidity Humidity may predispose the patient to episodes of disordered breathing during sleep. Pollution Pollution may predispose the patient to episodes of disordered breathing during sleep. Posture Posture may be used to determine if the patient is asleep. Posture may predispose the patient to disordered breathing. Time Used to establish historical sleep time. Ambient noise level Noise level may affect sleep quality. Location Patient location may used to determine if the patient is in bed as a part of sleep detection. Altitude Altitude may predispose the patient to episodes of disordered breathing and may affect sleep quality. Barometric Pressure Barometric pressure may predispose the patient to episodes of disordered breathing. Proximity to bed May be used to determine if patient is in bed. Historical sleep time May be used in connection with sleep detection. Medical history History of medical disorders, e.g., CHF, that are associated with disordered breathing such as Cheyne- Stokes respiration. Age Age is associated with increased risk of disordered breathing, RLS and other sleep disruptive disorders. Weight Associated with sleep disordered breathing, e.g., Gender obstructive sleep apnea. Obesity Neck size Patient reported drug, Patient drug, alcohol and nicotine use may affect sleep alcohol, nicotine use quality. Psychological history Psychological factors, e.g., clinical depression may be associated with insomnia. Emotional state Emotional state, e.g., stress, anxiety, euphoria, may affect sleep quality. Daytime sleepiness May be used to evaluate sleep quality. Patient perceptions of sleep quality

FIG. 2 illustrates a block diagram of a sleep quality data system 200 configured in accordance with embodiments of the invention. In this implementation, the sleep quality data system 200 may use signals acquired from a variety of sources to collect data relevant to sleep quality. The collected data may be stored in the memory 280 of a data collection unit 250 and/or transmitted to a sleep quality analysis unit 290 for further processing. It is contemplated that at least one, some, or all components of the system 200 are implanted in the patient.

The sleep quality data system 200 may use patient-internal sensors 210 implanted within the body of the patient to detect physiological conditions relevant to sleep quality. The conditions detected using patient-internal sensors 210 may include, for example, heart rate, respiratory pattern, and patient activity.

The system 200 may also use patient-external sensors 220 to detect physiological or non-physiological patient conditions. In one example configuration, whether the patient is snoring may be useful in evaluating sleep quality. Snoring data may be detected using an external microphone and transferred to the sleep quality data collection unit 250. In another configuration, ambient temperature and humidity may be factors related to the patient's sleep quality. The ambient temperature and humidity of the patient's room may be sensed using sensors located near patient. Signals from the temperature and humidity sensors may be transmitted to the data collection unit 250. Limb and/or jaw movements may be sensed using patient-external accelerometers and/or other sensors placed in appropriate locations on or near the patient and transmitted to the data collection unit 250.

Information relevant to sleep quality may also be reported 240 by the patient. According to embodiments of the invention, the patient's self-described conditions, including medication use, tobacco use, perceptions of sleep quality, and/or psychological or emotional state, for example, may be relevant to sleep quality assessment. The patient may enter information about these conditions through an appropriate interface device, such as a medical device programmer, coupled to the sleep quality data collection unit 250.

Some information related to sleep quality may be accessible through information systems 230, including network-based systems. For example, information about the patient's present cardiac, respiratory, or other therapy may be downloaded from an external device via a wireless or wired network. In another example, information about conditions affecting the patient, such as local air quality data, may be accessed through an internet-connected website.

The patient-internal sensors 210, patient-external sensors 220, patient-reported input devices 240, and information systems 230, may be coupled to the data collection unit 250 in a variety of ways. In one example, one or more of the sensors 210, 220, patient-reported input devices 240, and information systems 230 have wireless communication capabilities, such as a wireless Bluetooth communications link, or other proprietary communications protocol. In this implementation, the devices having wireless communication capabilities may remotely transmit signals to the data collection unit 250. In this application, the data collection unit 250 may be configured as an implantable or patient-external device. In other implementations, one or more of the patient-internal sensors 210, patient-external sensors 220, patient-reported input devices 240, and information systems 230 may be coupled to the data collection unit 250 through leads or other wired connections.

The implantable or patient-external data collection unit 250 includes detection circuitry 260 for processing signals from the sensors 210, 220, patient-reported input devices 240, and information systems 230. The detection circuitry 260 may include, for example, amplifiers, filters, A/D converters, signal processors and/or sensor driver circuitry configured to provide sensor signals used in the evaluation of sleep quality. The data collection unit 250 may further include wireless communication circuitry 270 for receiving and transmitting signals to wirelessly connected components.

In one embodiment, the sleep quality data system 200 collects data from the sensors 210, 220, input devices 240, and information systems 230, and stores the collected data in memory 280 prior to further processing or transmission. In another embodiment, the sleep quality data system 200 may transmit the collected data to a separate device (not shown) for storage, analysis, or display.

In a further embodiment, the sleep quality data system 200 may evaluate or further process the collected sleep quality data. For this purpose, the sleep quality data system 200 may optionally include a sleep quality analysis unit 290. In one configuration, the data collection unit 250 and the sleep quality analysis unit 290 are arranged in separate devices. In such a configuration, the data collection unit 250 transfers the collected sleep quality data to the sleep quality analysis unit 290 through a wireless or wired connection. In another configuration, the sleep quality analysis unit 290 and the data collection unit 250 are arranged within the same device which may be a patient-external device or a fully or partially implantable device.

The sleep quality analysis unit 290 may include one or more subsystems useful in sleep quality assessment. The subsystems may include, for example a sleep detector 292 used to detect sleep onset, sleep offset, and arousal, for example. The sleep detector may also detect sleep stages, including the various stages of NREM and REM sleep. The sleep quality analysis unit 290 may include circuitry to detect various sleep-related disorders. For example, the sleep quality analysis unit 290 may include circuitry 294 for detecting disordered breathing and circuitry 295 for detecting abnormal nocturnal movements. Further, the sleep quality analysis unit 290 may include a processor for evaluating sleep quality 296, for example, by calculating one or more metrics quantifying the patient's sleep quality.

FIG. 3 illustrates a sleep quality data system 305 incorporated within a cardiac rhythm management system (CRM) 300. The CRM 300 may include, for example, a cardiac therapy module 320 including a pacemaker 322 and an arrhythmia detector/therapy unit 324. The cardiac therapy module 320 is coupled to a lead system having electrodes 331 implantable within the patient's body. The implanted electrodes 331 are arranged to receive signals from the heart 330 and deliver stimulation therapy to the heart 330. Cardiac signals sensed using the implanted electrodes 331 are received by a cardiac signal detector 350 coupled to the cardiac therapy module 320.

The cardiac therapy module 320 analyzes the cardiac signals to determine an appropriate therapy to treat arrhythmia conditions affecting the heart 330. The cardiac therapy may include pacing therapy controlled by the pacemaker 322 to treat cardiac rhythms that are too slow. The pacemaker 322 controls the delivery of periodic low energy pacing pulses to ensure that the periodic contractions of the heart are maintained at a hemodynamically sufficient rate.

The cardiac therapy may also include therapy to terminate tachyarrhythmia, wherein the heart rate is too fast. The arrhythmia detector/therapy unit 324 analyzes cardiac signals received from the cardiac signal detector 350 to recognize tachyarrhythmias including atrial or ventricular tachycardia or fibrillation. The arrhythmia detector/therapy unit 324 recognizes cardiac signals indicative of tachyarrhythmia and delivers high energy stimulations to the heart 330 through the implanted electrodes 331 to terminate the arrhythmias.

Various input devices, including implantable sensors 381, patient-external sensors 382, patient input devices 384, and information systems 383 may be coupled to the CRM 300. These devices 381, 382, 383, 384 may be used to provide information about physiological and/or non-physiological conditions affecting the patient relevant to sleep quality, such as the representative set of patient conditions listed in Table 1 above.

The CRM 300 includes signal detection circuitry 360 for receiving and processing signals from the various sensors and input devices 381, 382, 384, 383. As previously discussed, the signal detection circuitry 360 may include signal processing circuitry configured to amplify, digitize, or otherwise process signals representing the sensed sleep quality conditions. In the illustrated implementation, the patient input devices 384, patient-external sensors 382, and information systems 383 are wirelessly coupled to the CRM 300. The patient-internal sensors 381 may be coupled to the CRM 300 through leads, through a wireless link, or integrated within or on the housing of the CRM 300 (e.g., integral accelerometer).

In one embodiment, the sleep quality data system 305 incorporated within the CRM 300 collects data from cardiac electrodes 331, patient-internal sensors 381, patient-external sensors 382, patient input devices 384, and information systems 383 and stores the collected data in memory. The sleep quality data system may transmit the collected data to a separate device, such as the CRM programmer 315 or other device, periodically as required or desired.

In another embodiment, the CRM sleep quality data system 305 may perform further processing and/or evaluation of the sleep quality data. For this purpose, the CRM sleep quality data system 305 may include a sleep quality analysis unit 340 coupled to the signal detector 360. The sleep quality analysis unit 340 may include one or more components for evaluating the patient's sleep quality. For example, the sleep quality analysis unit 340 may include sleep detection circuitry 341, disordered breathing detection circuitry 342, abnormal nocturnal movement detection circuitry 344, and a sleep quality processor 343, as previously described in connection with FIG. 2.

The cardiac therapy module 320, signal detector 360, and sleep quality analysis unit 340 operate in cooperation with a memory unit 370. The memory unit 370 may store parameters associated with cardiac therapy in addition to diagnostic or other data related to cardiac functioning and sleep quality. A communication unit 310 located within the CRM 300 may be used to transmit programming information and collected data from the CRM 300 to an external device such as a programmer 315.

Sleep quality assessment involves a reliable method for discriminating between a state of sleep and a state of wakefulness. One method of detecting sleep involves comparing one or more detected physiological conditions to thresholds indicative of sleep. When the detected conditions are consistent with thresholds indicating sleep, then sleep onset is declared. For example, decreased patient activity is a condition associated with sleep. When the patient's activity falls below a predetermined threshold, the system declares the onset of sleep. When the patient's activity rises above the threshold, the system declares the end of sleep. In a similar manner, a number of patient conditions, such as heart rate, respiration rate, brain wave activity, etc., may be compared individually or collectively compared to thresholds or other indices to detect sleep.

An enhanced method of sleep detection is described in commonly owned U.S. Pat. No. 7,189,204, which is incorporated herein by reference. The method involves adjusting a sleep threshold associated with a first patient condition using a second patient condition. The first patient condition is compared to the adjusted threshold to determine if the patient is asleep or awake.

FIG. 4 is a block diagram of a sleep detection unit 400 that may be used as part of a sleep quality data system according to embodiments of the invention. The sleep detection unit 400 uses a number of sensors 401, 402, 403 to sense sleep-related patient conditions. A representative set of sleep-related conditions include, for example, patient activity, patient location, posture, heart rate, QT interval, eye movement, respiration rate, transthoracic impedance, tidal volume, minute ventilation, brain activity, muscle tone, body temperature, time of day, and blood oxygen level.

According to embodiments of the invention, a first sleep-related condition detected using a sleep detection sensor 401 is compared to a sleep threshold for detecting the onset and termination of sleep. A second sleep-related condition, detected using a threshold adjustment sensor 402, is used to adjust the sleep threshold. Although the example described herein involves one sleep detection sensor 401 and one threshold adjustment sensor 402, any number of thresholds or other indices corresponding to a number of sleep detection sensors may be used. Furthermore, conditions detected using any number of adjustment sensors may be used to adjust the thresholds or indices of a plurality of sleep detection signals. Additional sleep-related signals derived from one or more confirmation sensors 403 may optionally be used to confirm the onset or termination of the sleep condition.

Signals derived from the sensors 401, 402, 403 are received by a sensor driver/detection circuitry 410 that may include, for example, amplifiers, signal processing circuitry, and/or ND conversion circuitry for processing each sensor signal. The sensor driver/detection system 410 may further include sensor drive circuitry required to activate the sensors 401, 402, 403.

The sensor signal detection system 410 is coupled to a sleep detector 430. The sleep detector 430 is configured to compare the level of a first sleep-related condition detected using the sleep detection sensor 401 to a sleep threshold adjusted by a second sleep-related condition detected using the threshold adjustment sensor 402. A determination of sleep onset or sleep termination may be made by the sleep detector 430 based on the comparison. The onset or termination of sleep may optionally be confirmed using patient conditions derived using a sleep confirmation sensor 403.

FIG. 5 is a flow chart illustrating a method of detecting sleep used in a sleep quality data system configured according to principles of the invention. A sleep threshold associated with a first sleep-related patient condition is established 505. The sleep threshold may be determined from clinical data of a sleep threshold acquired using a group of subjects, for example. The sleep threshold may also be determined using historical data taken from the particular patient for whom the sleep condition is to be detected.

First and second sleep-related conditions are detected 510, 520. The first and the second sleep-related conditions may be detected using sensors implanted in the patient, attached externally to the patient or located remote from the patient, for example, as previously described in connection with FIG. 3. The first and the second sleep-related conditions may include any condition associated with sleep and are not limited to the representative sleep-related conditions listed above.

The sleep threshold established for the first sleep-related condition is adjusted using the second sleep-related condition 530. For example, if the second sleep-related condition indicates a high level of activity that is incompatible with a sleep state, the sleep threshold of the first sleep-related condition may be adjusted downward to require sensing a decreased level of the first sleep-related condition before a sleep condition is detected.

If the first sleep-related condition is consistent with sleep according to the adjusted sleep threshold 540, sleep is detected 550. If the first sleep-related condition is not consistent with sleep using the adjusted sleep threshold, the first and the second sleep-related conditions continue to be detected 510, 520 and the threshold adjusted 530 until sleep is detected 550.

The flow chart of FIG. 6 illustrates a method for detecting sleep using accelerometer and MV signals according to embodiments of the invention. In the method illustrated in FIG. 6, an accelerometer and a minute ventilation sensor are used to detect patient activity and patient respiration conditions, respectively. A preliminary sleep threshold is determined 610 with respect to the patient activity condition sensed by the accelerometer. The preliminary sleep threshold may be determined from clinical data derived from a group of subjects or from historical data taken from the patient over a period of time.

The activity condition of the patient is monitored 620 using an accelerometer that may be incorporated in an implantable cardiac rhythm management system as described in connection with FIG. 3. Alternatively, the accelerometer may be attached externally to the patient. The patient's MV condition is monitored 625, for example, using a transthoracic impedance sensor. A transthoracic impedance sensor may be implemented as a component of an implantable CRM device.

In this embodiment, the patient's activity represents the sleep detection condition and is compared to the sleep threshold. The patient's MV is used as the threshold adjustment condition to adjust the sleep threshold. In addition, in this example, the patient's heart rate is monitored 630 and used to provide a sleep confirmation condition.

The sleep threshold adjustment is accomplished using the patient's MV condition to adjust the activity sleep threshold. If the patient's MV condition is low relative to an expected MV level associated with sleep, the activity sleep threshold is increased. Similarly, if the patient's MV level is high relative to an expected MV level associated with sleep, the activity sleep threshold is decreased. Thus, when the patient's MV level is high, less activity is required to make the determination that the patient is sleeping. Conversely when the patient's MV level is relatively low, a higher activity level may result in detection of sleep. The use of two sleep-related conditions to determine the patient's sleep state enhances the accuracy of sleep detection over previous methods.

Various signal processing techniques may be employed to process the raw sensor signals. For example, a moving average of a plurality of samples of the sensor signals may be calculated. Furthermore, the sensor signals may be amplified, filtered, digitized or otherwise processed.

If the MV level is high 635 relative to an expected MV level associated with sleep, the activity sleep threshold is decreased 640. If the MV level is low 635 relative to an expected MV level associated with sleep, the activity sleep threshold is increased 645.

If the patient's activity level is less than or equal to the adjusted sleep threshold 650, and if the patient is currently in a sleep state 665, then the patient's heart rate is checked 680 to confirm that the patient is asleep. If the patient's heart rate is compatible with sleep 680, then sleep onset is determined 690. If the patient's heart rate is incompatible with sleep, then the patient's sleep-related conditions continue to be monitored.

If the patient's activity level is less than or equal to the adjusted sleep threshold 650 and if the patient is currently in a sleep state 665, then a continuing sleep state is determined and the patient's sleep-related conditions continue to be monitored for sleep termination to occur.

If the patient's activity level is greater than the adjusted sleep threshold 650 and the patient is not currently in a sleep state 660, then the patient's sleep-related conditions continue to be monitored until sleep onset is detected 690. If the activity level is greater than the adjusted sleep threshold 650 and the patient is currently in a sleep state 660, then sleep termination is detected 670.

The graphs of FIGS. 7-10 illustrate the adjustment of the activity sleep threshold. The relationship between patient activity and the accelerometer and MV signals is trended over a period of time to determine relative signal levels associated with sleep. The graph of FIG. 7 illustrates the patient's activity as indicated by an accelerometer. The patient's heart rate for the same period is shown in the graph of FIG. 8. The accelerometer signal indicates a period of sleep associated with a relatively low level of activity beginning slightly before 23:00 and continuing through 6:00. The patient's heart rate appropriately tracks the activity level indicated by the accelerometer indicating a similar period of decreased heart rate corresponding to sleep. The signal level of the accelerometer during known periods of sleep may be used to establish a threshold for sleep detection.

FIG. 9 is a graph of the patient's minute ventilation signal over time. Historical data of minute ventilation is graphed over an 8 month period. The minute ventilation data may be used to determine the minute ventilation signal level associated with sleep. In this example, a composite minute ventilation graph using the historical data presents a roughly sinusoidal shape with the relatively low minute ventilation levels occurring during the period approximately from hours 21:00 through 8:00. The decreased minute ventilation level is associated with periods of sleep. The minute ventilation level associated with sleep is used to implement sleep threshold adjustment.

FIG. 10 illustrates adjustment of the activity sleep threshold using the MV data. The initial sleep threshold 1010 is established using the baseline activity data acquired as discussed above. If the patient's MV level is low relative to an expected MV level associated with sleep, the activity sleep threshold is increased 1020. If the patient's MV level is high relative to an expected MV level associated with sleep, the activity sleep threshold is decreased 1030. When the patient's MV level is high, less activity detected by the accelerometer is required to make the determination that the patient is sleeping. However, if the patient's MV level is relatively low, a higher activity level may result in detection of sleep. The use of two sleep-related signals to establish and adjust a sleep threshold enhances the accuracy of sleep detection over previous methods.

Additional sleep-related conditions may be sensed and used to improve the sleep detection method described above. For example, a posture sensor may be used to detect the posture of the patient and used to confirm sleep. If the posture sensor signal indicates an upright posture, then the posture sensor signal may be used to override a determination of sleep using the sleep detection and threshold adjustment conditions. Other conditions may also be used in connection with sleep determination or confirmation, including the representative set of sleep-related conditions indicated above. In another example, a proximity to bed sensor may be used alone or in combination with a posture sensor to detect that the patient is in bed and is lying down.

A sleep detection system may detect sleep onset, termination, arousals as well as the sleep stages, including REM and non-REM sleep. REM sleep may be discriminated from NREM sleep, for example, by examining one or more signals indicative of REM, e.g., muscle atonia, rapid eye movements, or EEG signals. Methods and systems for detecting REM sleep that are particularly useful for patients with implantable devices are discussed in commonly owned U.S. Pat. No. 8,192,376 and incorporated herein by reference. Various conditions indicative of sleep state may be detected using sensors, e.g., electroencephalogram (EEG), electrooculogram (EOG), or electromyogram (EMG) sensors, coupled through wired or wireless connections to the sleep detection circuitry. The sleep detection circuitry may analyze the various patient conditions sensed by the sensors to track the patient's sleep through various sleep states, including REM and NREM stages.

Returning to FIG. 3, the sleep quality data system 300 may also employ disordered breathing detection circuitry 342 to detect episodes of disordered breathing. Disordered breathing may be detected in numerous ways using one or more of the patient conditions listed in Table 1. Methods and systems for detecting disordered breathing are described in commonly owned U.S. Pat. No. 7,252,640, which is incorporated herein by reference. According to this approach, disordered breathing may be detected by examining characteristics of the patient's respiration patterns to determine if the respiration patterns are consistent with disordered breathing.

FIG. 11 illustrates a normal respiration pattern as represented by a transthoracic impedance sensor signal. The transthoracic impedance increases during respiratory inspiration and decreases during respiratory expiration. During NREM sleep, a normal respiration pattern includes regular, rhythmic inspiration—expiration cycles without substantial interruptions.

In one embodiment, detection of disordered breathing, including, for example, sleep apnea and hypopnea, involves defining and examining a number of respiratory cycle intervals. FIG. 12 illustrates respiration intervals used for disordered breathing detection according to an embodiment of the invention. A respiration cycle is divided into an inspiration period corresponding to the patient inhaling, an expiration period, corresponding to the patient exhaling, and a non-breathing period occurring between inhaling and exhaling. Respiration intervals are established using inspiration 1210 and expiration 1220 thresholds. The inspiration threshold 1210 marks the beginning of an inspiration period 1230 and is determined by the transthoracic impedance signal rising above the inspiration threshold 1210. The inspiration period 1230 ends when the transthoracic impedance signal is maximum 1240. A maximum transthoracic impedance signal 1240 corresponds to both the end of the inspiration interval 1230 and the beginning of the expiration interval 1250. The expiration interval 1250 continues until the transthoracic impedance falls below an expiration threshold 1220. A non-breathing interval 1260 starts from the end of the expiration period 1250 and continues until the beginning of the next inspiration period 1270.

Detection of sleep apnea and severe sleep apnea according to embodiments of the invention is illustrated in FIG. 13. The patient's respiration signals are monitored and the respiration cycles are defined according to inspiration 1330, expiration 1350, and non-breathing 1360 intervals as described in connection with FIG. 12. A condition of sleep apnea is detected when a non-breathing period 1360 exceeds a first predetermined interval 1390, denoted the sleep apnea interval. A condition of severe sleep apnea is detected when the non-breathing period 1360 exceeds a second predetermined interval 1395, denoted the severe sleep apnea interval. For example, sleep apnea may be detected when the non-breathing interval exceeds about 10 seconds, and severe sleep apnea may be detected when the non-breathing interval exceeds about 20 seconds.

Hypopnea is a condition of disordered breathing characterized by abnormally shallow breathing. FIGS. 14A-B are graphs of respiration patterns derived from transthoracic impedance measurements. The graphs compare the tidal volume of a normal breathing cycle to the tidal volume of a hypopnea episode. FIG. 14A illustrates normal respiration tidal volume and rate. As shown in FIG. 14B, hypopnea involves a period of abnormally shallow respiration.

According to an embodiment of the invention, hypopnea is detected by comparing a patient's respiratory tidal volume to a hypopnea tidal volume threshold. The tidal volume for each respiration cycle may be derived from transthoracic impedance measurements. The hypopnea tidal volume threshold may be established using clinical results providing a representative tidal volume and duration for hypopnea events. In one configuration, hypopnea is detected when an average of the patient's respiratory tidal volume taken over a selected time interval falls below the hypopnea tidal volume threshold.

FIG. 15 is a flow chart illustrating a method of apnea and/or hypopnea detection according to embodiments of the invention. Various parameters are established 1501 before analyzing the patient's respiration for disordered breathing episodes, including, for example, inspiration and expiration thresholds, sleep apnea interval, severe sleep apnea interval, and hypopnea tidal volume threshold.

The patient's transthoracic impedance is detected 1505. If the transthoracic impedance exceeds 1510 the inspiration threshold, the beginning of an inspiration interval is detected 1515. If the transthoracic impedance remains below 1510 the inspiration threshold, then the impedance signal is checked 1505 periodically until inspiration 1515 occurs.

During the inspiration interval, the patient's transthoracic impedance is monitored until a maximum value of the transthoracic impedance is detected 1520. Detection of the maximum value signals an end of the inspiration period and a beginning of an expiration period 1535.

The expiration interval is characterized by decreasing transthoracic impedance. When the transthoracic impedance falls below 1540 the expiration threshold, a non-breathing interval is detected 1555.

If the transthoracic impedance does not exceed 1560 the inspiration threshold within a first predetermined interval 1565, denoted the sleep apnea interval, then a condition of sleep apnea is detected 1570. Severe sleep apnea is detected 1580 if the non-breathing period extends beyond a second predetermined interval 1575, denoted the severe sleep apnea interval.

When the transthoracic impedance exceeds 1560 the inspiration threshold, the tidal volume from the peak-to-peak transthoracic impedance is calculated 1585. The peak-to-peak transthoracic impedance provides a value proportional to the tidal volume of the respiration cycle. This value is compared 1590 to a hypopnea tidal volume threshold. If the peak-to-peak transthoracic impedance is consistent with 1590 the hypopnea tidal volume threshold for a predetermined time 1592, then a hypopnea cycle is detected 1595.

Additional sensors, such as motion sensors and/or posture sensors, may be used to confirm or verify the detection of a sleep apnea or hypopnea episode. The additional sensors may be employed to prevent false or missed detections of sleep apnea or hypopnea due to posture and/or motion related artifacts.

Another embodiment of the invention involves classifying respiration patterns as disordered breathing episodes based on the breath intervals and/or tidal volumes of one or more respiration cycles within the respiration patterns. According to this embodiment, the duration and tidal volumes associated with a respiration pattern are compared to duration and tidal volume thresholds. The respiration pattern may be determined to represent a disordered breathing episode based on the comparison.

According to this embodiment, a breath interval 1630 is established for each respiration cycle. A breath interval represents the interval of time between successive breaths, as illustrated in FIG. 16. A breath interval 1630 may be defined in a variety of ways, for example, as the interval of time between successive maxima 1610, 1620 of the impedance signal waveform.

Detection of disordered breathing, in accordance with methods of the invention, involves the establishment of a duration threshold and a tidal volume threshold. If a breath interval exceeds the duration threshold, an apnea event is detected. Detection of sleep apnea, in accordance with this embodiment, is illustrated in the graph of FIG. 16. Apnea represents a period of non-breathing. A breath interval 1630 exceeding a duration threshold 1640 comprises an apnea episode.

Hypopnea may be detected using a duration threshold and a tidal volume threshold. A hypopnea event represents a period of shallow breathing greater than the duration threshold. Each respiration cycle in a hypopnea event is characterized by a tidal volume less than the tidal volume threshold. Further, the decreased tidal volume cycles persist longer than the duration threshold.

A hypopnea detection approach, in accordance with embodiments of the invention, is illustrated in FIG. 17. Shallow breathing is detected when the tidal volume of one or more breaths is below a tidal volume threshold 1710. If the shallow breathing continues for an interval greater than a duration threshold 1720, then the breathing pattern represented by the sequence of shallow respiration cycles, is classified as a hypopnea event.

FIGS. 18A and 18B provide charts illustrating classification of individual disordered breathing events and combination of periodic breathing events, respectively. As illustrated in FIG. 18A, individual disordered breathing events may be grouped into apnea, hypopnea, tachypnea and other disordered breathing events. Apnea events are characterized by an absence of breathing. Intervals of reduced respiration are classified as hypopnea events. Tachypnea events include intervals of rapid respiration characterized by an elevated respiration rate.

As illustrated in FIG. 18A, apnea and hypopnea events may be further subdivided as either central events, e.g., caused either by central nervous system dysfunction, or obstructive events, e.g., caused by upper airway obstruction. A tachypnea event may be further classified as a hyperpnea event, represented by rapid deep breathing (hyperventilation). A tachypnea event may alternatively be classified as rapid shallow breathing, typically of prolonged duration.

FIG. 18B illustrates classification of periodic disordered breathing events. Periodic breathing may be classified as obstructive, central or mixed. Obstructive periodic breathing is characterized by cyclic respiratory patterns with an obstructive apnea or hypopnea event in each cycle. In central periodic breathing, the cyclic respiratory patterns include a central apnea or hypopnea event in each cycle. Periodic breathing may also be of mixed origin. In this case, cyclic respiratory patterns have a mixture of obstructive and central apnea events in each cycle. Cheyne-Stokes respiration is a particular type of periodic breathing characterized by a gradual waxing and waning of tidal volume and having a central apnea and hyperpnea event in each cycle. Other manifestations of periodic breathing are also possible.

As illustrated in FIGS. 18C-G, a respiration pattern detected as a disordered breathing episode may include only an apnea respiration cycle 1810 (FIG. 18C), only hypopnea respiration cycles 1850 (FIG. 18F), or a mixture of hypopnea and apnea respiration cycles 1820 (FIG. 18D), 1830 (FIG. 18E), 1860 (FIG. 18G). A disordered breathing event 1820 may begin with an apnea respiration cycle and end with one or more hypopnea cycles. In another pattern, the disordered breathing event 1830 may begin with hypopnea cycles and end with an apnea cycle. In yet another pattern, a disordered breathing event 1860 may begin and end with hypopnea cycles with an apnea cycle in between the hypopnea cycles. Analysis of the characteristic respiration patterns associated with various types of disordered breathing may be used to detect, classify and evaluate disordered breathing episodes.

FIG. 19 is a flow chart of a method for detecting disordered breathing by classifying breathing patterns using breath intervals in conjunction with tidal volume and duration thresholds as previously described above. In this example, a duration threshold and a tidal volume threshold are established for determining both apnea and hypopnea breath intervals. An apnea episode is detected if the breath interval exceeds the duration threshold. A hypopnea episode is detected if the tidal volume of successive breaths remains less than the tidal volume threshold for a period in excess of the duration threshold. Mixed apnea/hypopnea episodes may also occur. In these cases, the period of disordered breathing is characterized by shallow breaths or non-breathing intervals. During the mixed apnea/hypopnea episodes, the tidal volume of each breath remains less than the tidal volume threshold for a period exceeding the duration threshold.

The patient's respiration cycles are determined, for example, using transthoracic impedance signals. Each breath 1910 is characterized by a breath interval, i.e., the interval of time between two impedance signal maxima and a tidal volume (TV). If a breath interval exceeds 1915 the duration threshold, then the respiration pattern is consistent with an apnea event, and an apnea event trigger is turned on 1920. If the tidal volume of the breath interval exceeds 1925 the tidal volume threshold, then the breathing pattern is characterized by two respiration cycles of normal volume separated by a non-breathing interval. This pattern represents a purely apneic disordered breathing event, and apnea is detected 1930. Because the final breath of the breath interval was normal, the apnea event trigger is turned off 1932, signaling the end of the disordered breathing episode. However, if the tidal volume of the breath interval does not exceed 1925 the tidal volume threshold, the disordered breathing period is continuing and the next breath is checked 1910.

If the breath interval does not exceed 1915 the duration threshold, then the tidal volume of the breath is checked 1935. If the tidal volume does not exceed 1935 the tidal volume threshold, the breathing pattern is consistent with a hypopnea cycle and a hypopnea event trigger is set on 1940. If the tidal volume exceeds the tidal volume threshold, then the breath is normal.

If a period of disordered breathing is in progress, detection of a normal breath signals the end of the disordered breathing. If disordered breathing was previously detected 1945, and if the disordered breathing event duration has not exceeded 1950 the duration threshold, and the current breath is normal, then no disordered breathing event is detected 1955. If disordered breathing was previously detected 1945, and if the disordered breathing event duration has extended for a period of time exceeding 1950 the duration threshold, and the current breath is normal, then the disordered breathing trigger is turned off 1960. In this situation, the duration of the disordered breathing episode was of sufficient duration to be classified as a disordered breathing episode. If an apnea event was previously triggered 1965, then an apnea event is declared 1970. If a hypopnea was previously triggered 1965, then a hypopnea event is declared 1975.

As previously discussed in connection with FIG. 3, a sleep quality analysis unit 340 may incorporate an abnormal nocturnal movement detector 344 to evaluate the movements of a patient during the night to detect nocturnal movement disorders such as RLS, PLMD, and/or bruxism. The patient may be instrumented with accelerometers located on the limbs or jaw, for example, to sense patient movement. Excessive movement, or movements having a characteristic pattern, e.g., periodic limb or jaw movements, may be classified as abnormal nocturnal movements. For example, bruxism is a sleep disorder wherein the patient grinds his teeth during sleep. An accelerometer attached to the patient's jaw may be used to sense movement of the jaw. Signals from the jaw accelerometer may be transferred to the abnormal movement detector for evaluation to determine if the movements are excessive or unusually periodic, indicating bruxism. In a similar application, accelerometers attached to the patient's limbs may generate signals used by the abnormal movement detector 344 to detect and classify disorders such as RLS and PLMD.

FIG. 20 illustrates a patient 2010 instrumented with a sleep quality data system 2000 according to embodiments of the invention. The sleep quality data system collects sleep quality data from the patient using a number of sensors 2011-2019. In one configuration, the collected data is analyzed by a sleep quality analysis unit that may be an integrated component of an implantable sleep quality data collection and analysis unit 2020. In another configuration, the collected data may be downloaded to a patient-external device 2030 for storage, analysis, or display.

In the implementation illustrated in FIG. 20, the sleep quality data system 2000 includes an implantable sleep quality data collection and analysis unit 2020 coupled to a number of sensors 2011-2019. In this example, the sensors include an EGM sensor 2016 for detecting heart rate and heart rate variability conditions. A transthoracic impedance sensor 2017 is used to detect the respiration conditions of the patient, including, for example, minute ventilation, respiration rate, and tidal volume. An activity detector, e.g., accelerometer, 2015 may be used to detect patient activity conditions. The sleep quality data system detects patient conditions including the patient's posture and location using a posture sensor 2014 and a proximity to bed sensor 2013, respectively. The sleep quality data system senses the patient's brain activity using EEG sensors 2011 and the patient's eye movements using EOG sensors 2012. Jaw and limb movements are sensed using accelerometers attached to the patient's jaw 2018 and legs 2019.

In this application, the sleep quality data collection and analysis unit 2020 is configured to track the patient's heart rate, heart rate variability, minute ventilation, respiration rate, tidal volume, posture, proximity to bed, brain activity, eye movements, jaw movements and leg movements. At periodic intervals, the system samples signals from the sensors and stores data regarding the detected conditions in memory circuitry within the sleep quality data collection and analysis unit 2020. The sleep quality data collection and analysis unit 2020 may additionally access an external input unit 2030 to detect patient reported conditions, for example, recent tobacco and medication use by the patient. Further, the sleep quality data collection and analysis unit 2020 may monitor conditions using one or more external sensors. In the illustrated example, a thermometer 2035 is coupled through the external programmer 2030 and a pollution website 2040 is accessible to the sleep quality data collection and analysis unit 2020 through the internet 2050.

The sleep quality data collection and analysis unit 2020 may operate to acquire data during periods of both sleep and wakefulness. It may be beneficial, for example, to track changes in particular conditions measured during periods of wakefulness that are associated with sleep disordered breathing. For example, some patients who suffer from sleep apnea experience changes in heart rate variability, blood pressure variability, and/or sympathetic nerve activity during periods of wakefulness. Detection and analysis of the physiological changes attributable to sleep disorders and measurable during the time the patient is awake provides a more complete picture of sleep quality.

In another example, the patient's sleep quality may be evaluated by determining the patient's activity level while the patient is awake. The activity level of the patient during the day may provide important information regarding the patient's sleep quality. For example, if the patient is very inactive during periods of wakefulness, this may indicate that the patient's sleep is of inadequate quality or duration. Such information may also be used in connection with assessing the efficacy of a particular sleep disorder therapy and/or adjusting the patient's sleep disorder therapy. Methods and systems for determining the patient's activity level and generally assessing the well-being of a patient are described in commonly owned U.S. Pat. No. 6,021,351 which is incorporated herein by reference.

The analysis unit 2020 may calculate one or more sleep quality metrics quantifying the patient's sleep quality. A representative set of the sleep quality metrics include, for example, sleep efficiency, sleep fragmentation, number of arousals per hour, denoted the arousal index (AI).

The analysis unit 2020 may also compute one or more metrics quantifying the patient's disordered breathing, such as the apnea hypopnea index (AHI) providing the number of apneas and hypopneas per hour, and the percent time in periodic breathing (% PB).

Further, metrics associated with sleep movement disorders may also be determined by the analysis unit 2020. Such metrics may include, for example, a general sleep movement disorder index (MDI) representing the number of abnormal movements arising from movement disorders such as restless leg syndrome, periodic limb movement disorder and bruxism per hour. In addition, specific indices may be calculated for each type of movement disorder, e.g., a bruxism index (BI) characterizing the number of jaw movements per hour, a RLS index (RLSI) characterizing the number of restless leg syndrome episodes per hour, and a PLM index (PLMI) characterizing the number of periodic limb movements experienced by the patient per hour.

In addition, percentage of sleep time during which the patient experiences movement disorders (% MD) may be calculated. Specific metrics relating to the percentage of time during which the patient experiences bruxism (% B), restless leg syndrome (% RLS), and periodic leg movement disorder (% PLMD) may also be determined.

Further, sleep summary metrics may be computed, either directly from the collected patient condition data, or by combining the above-listed sleep quality and sleep disorder metrics. In one embodiment, a composite sleep disordered respiration metric (SDRM) may be computed by combining the apnea hypopnea index AHI and the arousal index AI. The composite sleep disordered respiration metric (SDRM) may be computed as a linear combination of the AHI and AI as follows:
SDRM=c1*AHI+c2*AI  [1]

where c1 and c2 are constants chosen to balance the relative contributions of respiratory and arousal effects on sleep disturbance. The AHI may be monitored by performing disordered breathing detection based on transthoracic impedance measurements as previously described. The AI may be estimated, for example, by monitoring the patient activity, minute ventilation, and posture sensors for body motion indicating sleep termination or arousal. A more sensitive measure of arousal may be made using EEG signals. In this implementation, the constant c2 may be adjusted to reflect the increased sensitivity to arousal.

In another embodiment, an undisturbed respiration sleep time (URST) or undisturbed respiration sleep efficiency (URSE) may be computed based on the amount of time the patient spends asleep in bed without respiratory disturbance.

The URST or URSE metrics may be determined using three parameters: total time in bed (TIB), total time asleep (TA), and combined sleep time duration in disturbed respiration (STDR). Time in bed may be determined by a combination of posture sensing and sensing the proximity of the patient to bed. The posture condition of the patient may determined, for example, using an implantable multiaxis accelerometer sensor.

The patient's total time in bed (TIB) may be determined using a proximity to bed sensor. The proximity to bed sensor may use a receiver in the sleep quality data collection and analysis unit 2020 for receiving signals transmitted from a beacon 2070 located at the patient's bed 2060. If the proximity to bed receiver detects a signal of sufficient strength from the proximity to bed beacon 2070, then the receiver detects that the patient is in bed 2060.

Total time asleep (TA) may be determined using the sleep detection method described in more detail above. The total sleep time in disturbed respiration (STDR) may be determined, for example, based on detection of sleep and disordered breathing using the sleep and disordered breathing detection methods described above.

The patient's undisturbed respiration sleep time (URST) is calculated as:
URST=TA−STDR  [2]

where TA=total time asleep and STDR=sleep time in disturbed breathing. The undisturbed respiration sleep efficiency (USE) in percent is calculated
URSE=100*URST/TIB  [3]

where URST=undisturbed respiration sleep time and TIB=total time in bed.

Similar metrics may be calculated for movement disorders generally, or for specific movement disorders, e.g., RLS, PLMD, or bruxism. For example, the composite RLS, PLMD, and bruxism metrics, RLSM, PLMDM, and BM, respectively, may be calculated using equations similar in form to equation 1 above:
RLSM=c1*RLSI+c2*AI  [4]

where RLSI=number of restless leg movement syndrome episodes per hour, AI=number of arousals per hour, and c1 and c2 are constants chosen to balance the relative contributions of abnormal movement and arousal effects on sleep disturbance.
PLMDM=c1*PLMDI+c2*AI  [5]

where PLMDI=number of periodic leg movement syndrome episodes per hour, AI=number of arousals per hour, and c1 and c2 are constants chosen to balance the relative contributions of abnormal movement and arousal effects on sleep disturbance.
BM=c1*BMI+c2*AI  [6]

where BMI=number of bruxism movement episodes per hour, AI=number of arousals per hour, and c1 and c2 are constants chosen to balance the relative contributions of abnormal movement and arousal effects on sleep disturbance.

The patient's undisturbed movement sleep time (UMST) and undisturbed movement sleep efficiency (UMSE) may be calculated for each movement related disorder separately or in combination using equations similar in form to equations 2 and 3, above.

In addition, a composite sleep disorder index SDI quantifying the combined effect of both respiratory and movement disorders may be computed by combining the apnea hypopnea index (AHI), the movement disorder index (MDI), and the arousal index (AI).

A sleep disturbance index (SDI) may be computed as a linear combination of the AHI, and the combined disorder index DIc. The combined disorder index may include both abnormal breathing and movement components. For example, the sleep disturbance index SDI is characterizable by the equation:
SDI=c4*DIc+c3*AI,  [7]

where DIc is a combined disorder index of the form:
DIc=c41*DI1+c42*DI2  [7a]
In equation 7, c4 and c3 are constants chosen to balance the relative contributions of the combined disorder and arousal effects, respectively. The disorder index, DIc, may be used to characterize the effects of one or more sleep disorders, including, e.g., disorders associated with disturbed respiration and/or abnormal movements. The combined disorder index may represent only one disorder index, or may be a linear combination of two or more sleep disorder indices, e.g., the apnea/hypopnea index (AHI) and the abnormal movement disorder index (MDI). The constants c41 and c42 may be used as weighting factors associated with particular disorder indices.

The patient's undisturbed sleep time (UST) may be calculated:
UST=TA−STSD  [8]

where TA=total time asleep and STSD=sleep time spent in sleep disorders.

The undisturbed sleep efficiency (USE) in percent may be calculated:
USE=100*UST/TIB  [9]

where UST=undisturbed sleep time and TIB=total time in bed.

Sleep quality metrics, such as those described above, or other metrics, may be acquired and analyzed using the sleep quality data collection and analysis unit 2020. Sleep quality metrics, in addition to raw or processed data based on physiological and non-physiological conditions may determined periodically, e.g., daily, and stored or transmitted to another device. Such data can be presented to the patient's health care professional on a real-time basis, or as a long-term, e.g., month long or year long, trend of daily measurements.

The health care professional may access the data during clinic visits via programmer interrogation of the implanted device, through occasional or periodic trans-telephonic device interrogations, or through an automatic or “on-demand” basis in the context of an advanced patient management system. The health care professionals may use the sleep quality indicator trends alone or in conjunction with other device-gathered or clinical data to diagnose disorders and/or adjust the patient's device or medical therapy as needed to improve the patient's quality of sleep.

The present invention provides diagnostic, monitoring, and evaluation capabilities relating to sleep quality and may be particularly valuable in the context of an advanced patient management system. Undiagnosed sleep disorders can lead to increased morbidity and mortality, such as those arising from various respiratory and cardiovascular consequences. Routine monitoring of patient sleep quality may lead to improved diagnosis and treatment of these syndromes and their associated co-morbidities. The invention may provide less obtrusive sleep quality monitoring, particularly and is suited for patients having an implanted device. The present invention serves to improve diagnosis of sleep disorders by reducing the inconveniences, unnatural sleep environment issues, and expenses associated with sleep clinic polysomnogram studies.

The following commonly owned U.S. Patents Applications, some of which have been identified above, are hereby incorporated by reference in their respective entireties: U.S. Pat. Nos. 7,189,204, 7,252,640, 7,396,333, 7,680,537, 7,720,541.

Various modifications and additions can be made to the preferred embodiments discussed hereinabove without departing from the scope of the present invention. Accordingly, the scope of the present invention should not be limited by the particular embodiments described above, but should be defined only by the claims set forth below and equivalents thereof.

Claims

1. An implantable sleep quality evaluation device for implantation into a patient, comprising:

a detector system including one or more patient-internal sensors for detecting and determining a first measure related to a heart rate of the patient, a second measure related to a respiration of the patient, and a third measure related to an activity of the patient;
a memory; and
a sleep quality processor coupled to the detector system and configured to: determine a sleep condition of the patient based on the first measure related to the heart rate of the patient, the second measure related to the respiration of the patient, and the third measure related to the activity of the patient, in combination with one or more thresholds, wherein the sleep quality processor uses the second measure related to respiration to characterize a minute ventilation (MV) of the patient, and uses a measure related to minute ventilation (MV) of the patient in determining the sleep condition of the patient; and store the sleep condition into the memory of the implantable sleep quality evaluation device.

2. The device of claim 1, wherein the sleep quality processor repeatedly determines a new sleep condition of the patient over time.

3. The device of claim 2, wherein the sleep quality processor calculates at least one composite sleep metric based, at least in part, on two or more of the sleep conditions that are determined over time.

4. The device of claim 3, wherein the sleep quality processor is configured to trend over time the composite sleep metric.

5. The device of claim 1, wherein at least one of the one or more thresholds is dependent upon at least one of the first, second and third measures.

6. A method for assessing sleep quality, comprising:

detecting a first measure related to a heart rate of the patient and a second measure related to a respiration of the patient, wherein the first measure related to a heart rate of the patient is detected using one or more implanted pacemaker leads and the second measure related to the respiration of the patient is detected using one or more implanted transthoracic impedance sensors;
using an implantable device to determine one or more metrics associated with sleep quality based at least in part on the detected first measure related to the heart rate of the patient and the second measure related to the respiration of the patient, in combination with one or more thresholds, wherein at least one of the one or more thresholds is dependent upon at least one of the first and second measures; and
storing the one or more metrics into a memory of an implantable device.

7. The method of claim 6, wherein the second measure is used to characterize minute ventilation (MV) of the patient, and wherein the implantable device determines one or more metrics associated with sleep quality based at least in part on the minute ventilation (MV) of the patient.

8. The method of claim 6, wherein the second measure is used to characterize disordered breathing of the patient, and wherein the implantable device determines one or more metrics associated with sleep quality based at least in part on the disordered breathing of the patient.

9. The method of claim 6, further comprising repeating the detecting, using and storing steps over time.

10. The method of claim 6, further comprising detecting a third measure related to an activity of the patient, wherein the one or more metrics includes a composite sleep quality metric that is based at least in part on the detected first measure related to the heart rate of the patient, the second measure related to the respiration of the patient, and the detected third measure related to the activity of the patient.

11. The method of claim 10, further comprising detecting a fourth measure related to a posture of the patient, wherein the composite sleep quality metric is based at least in part on the detected first measure related to the heart rate of the patient, the second measure related to the respiration of the patient, the detected third measure related to the activity of the patient, and the fourth measure related to a posture of the patient.

12. The method of claim 10, wherein the third measure related to the activity of the patient is detected using an implanted accelerometer.

13. The method of claim 10, wherein determining the composite sleep quality metric comprises determining a sleep disturbance index.

14. The method of claim 10, wherein determining the composite sleep quality metric comprises determining an undisturbed sleep time metric.

15. The method of claim 10, wherein determining the composite sleep quality metric comprises determining an undisturbed sleep efficiency metric.

16. The method of claim 6, further comprising detecting a measure indicative of a movement disorder.

17. The method of claim 6, further comprising adjusting a cardiac or respiration therapy that is delivered to the patient via the implantable device based at least in part on one or more of the metrics.

18. An implantable sleep quality evaluation device for implantation into a patient, comprising:

a detector system including one or more patient-internal sensors for detecting and determining a first measure related to a heart rate of the patient, a second measure related to a respiration of the patient, and a third measure related to an activity of the patient;
a memory; and
a sleep quality processor coupled to the detector system and configured to: determine a sleep condition of the patient based on the first measure related to the heart rate of the patient, the second measure related to the respiration of the patient, and the third measure related to the activity of the patient, in combination with one or more thresholds; and store the sleep condition into the memory of the implantable sleep quality evaluation device;
wherein the detector system includes one or more patient-internal sensors for detecting and determining a fourth measure related to a patient's posture, and wherein the sleep quality processor is configured to determine the sleep condition of the patient based on the first measure related to the heart rate of the patient, the second measure related to the respiration of the patient, the third measure related to the activity of the patient, and the fourth measure related to the patient's posture, and in combination with one or more thresholds.

19. An implantable device for implantation into a patient, comprising:

one or more patient-internal sensors for detecting a first measure related to a heart rate of the patient and a second measure related to a respiration of the patient;
a memory; and
a processor in communication with the one or more patient-internal sensors and the memory, the processor configured to determine one or more metrics associated with sleep quality of the patient based on the first measure related to the heart rate of the patient and the second measure related to the respiration of the patient, the processor further configured to store the one or more metrics into the memory of the implantable device and to adjust a cardiac or respiration therapy that is delivered to the patient via the implantable device based at least in part on one or more of the metrics; and
a communications block for wirelessly transmitting the one or more metrics from the implantable device to a location remote from the patient.
Referenced Cited
U.S. Patent Documents
3650277 March 1972 Sjostrand et al.
4091818 May 30, 1978 Brownlee et al.
4312355 January 26, 1982 Funke
4312734 January 26, 1982 Nichols
4365636 December 28, 1982 Barker
4390405 June 28, 1983 Hahn et al.
4414982 November 15, 1983 Durkan
4648407 March 10, 1987 Sackner
4702253 October 27, 1987 Nappholz et al.
4721110 January 26, 1988 Lampadius
4777962 October 18, 1988 Watson et al.
4784162 November 15, 1988 Ricks et al.
4791931 December 20, 1988 Slate
4802485 February 7, 1989 Bowers et al.
4807629 February 28, 1989 Baudino et al.
4813427 March 21, 1989 Schlaefke et al.
4827943 May 9, 1989 Bornn et al.
4830008 May 16, 1989 Meer
4836219 June 6, 1989 Hobson et al.
4856524 August 15, 1989 Baker, Jr.
4860766 August 29, 1989 Sackner
4875477 October 24, 1989 Waschke et al.
4886064 December 12, 1989 Strandberg
4953551 September 4, 1990 Mehra et al.
4958632 September 25, 1990 Duggan
4961423 October 9, 1990 Canducci
4972842 November 27, 1990 Korten et al.
4982738 January 8, 1991 Griebel
5003975 April 2, 1991 Hafelfinger et al.
5010888 April 30, 1991 Jadvar et al.
5024222 June 18, 1991 Thacker
5047930 September 10, 1991 Martens et al.
5063927 November 12, 1991 Webb et al.
5074301 December 24, 1991 Gill
5101831 April 7, 1992 Koyama et al.
5111815 May 12, 1992 Mower
5123425 June 23, 1992 Shannon, Jr. et al.
5133353 July 28, 1992 Hauser
5146918 September 15, 1992 Kallok et al.
5156157 October 20, 1992 Valenta, Jr. et al.
5158089 October 27, 1992 Swezey et al.
5170784 December 15, 1992 Ramon et al.
5174287 December 29, 1992 Kallok et al.
5179945 January 19, 1993 Van Hofwegen et al.
5183038 February 2, 1993 Hoffman et al.
5188106 February 23, 1993 Nappholz et al.
5190035 March 2, 1993 Salo et al.
5199424 April 6, 1993 Sullivan et al.
5199428 April 6, 1993 Obel et al.
5203326 April 20, 1993 Collins
5209229 May 11, 1993 Gilli
5211173 May 18, 1993 Kallok et al.
5215082 June 1, 1993 Kallok et al.
5233983 August 10, 1993 Markowitz
5243979 September 14, 1993 Stein et al.
5243980 September 14, 1993 Mehra
5245995 September 21, 1993 Sullivan et al.
5259373 November 9, 1993 Gruenke et al.
5261400 November 16, 1993 Bardy
5275159 January 4, 1994 Griebel
5280791 January 25, 1994 Lavie
5292338 March 8, 1994 Bardy
5299118 March 29, 1994 Martens et al.
5300106 April 5, 1994 Dahl et al.
5306293 April 26, 1994 Zacouto
5314430 May 24, 1994 Bardy
5314459 May 24, 1994 Swanson et al.
5318592 June 7, 1994 Schaldach
5318593 June 7, 1994 Duggan
5318594 June 7, 1994 Limousin et al.
5318597 June 7, 1994 Hauck et al.
5330505 July 19, 1994 Cohen
5330507 July 19, 1994 Schwartz
5331966 July 26, 1994 Bennett et al.
5334221 August 2, 1994 Bardy
5353788 October 11, 1994 Miles
5356425 October 18, 1994 Bardy et al.
5363842 November 15, 1994 Mishelevich et al.
5372606 December 13, 1994 Lang et al.
5376103 December 27, 1994 Anderson et al.
5376106 December 27, 1994 Stahmann et al.
5377671 January 3, 1995 Biondi et al.
5391187 February 21, 1995 Freeman
5398682 March 21, 1995 Lynn
5404877 April 11, 1995 Nolan et al.
5411525 May 2, 1995 Swanson et al.
5411531 May 2, 1995 Hill et al.
5411539 May 2, 1995 Neisz
5417717 May 23, 1995 Salo et al.
5437285 August 1, 1995 Verrier et al.
5439482 August 8, 1995 Adams et al.
5441518 August 15, 1995 Adams et al.
5466245 November 14, 1995 Spinelli et al.
5468254 November 21, 1995 Hahn et al.
5476485 December 19, 1995 Weinberg et al.
5483969 January 16, 1996 Testerman et al.
5485851 January 23, 1996 Erickson
5487755 January 30, 1996 Snell et al.
5490502 February 13, 1996 Rapoport et al.
5507784 April 16, 1996 Hill et al.
5517983 May 21, 1996 Deighan et al.
5520176 May 28, 1996 Cohen
5520191 May 28, 1996 Karlsson et al.
5522382 June 4, 1996 Sullivan et al.
5522854 June 4, 1996 Ideker et al.
5522862 June 4, 1996 Testerman et al.
5527345 June 18, 1996 Infinger
5531779 July 2, 1996 Dahl et al.
5540732 July 30, 1996 Testerman
5540734 July 30, 1996 Zabara
5554177 September 10, 1996 Kieval et al.
5578061 November 26, 1996 Stroetmann et al.
5590648 January 7, 1997 Mitchell et al.
5591216 January 7, 1997 Testerman et al.
5593431 January 14, 1997 Sheldon
5601607 February 11, 1997 Adams
5603331 February 18, 1997 Heemels et al.
5605151 February 25, 1997 Lynn
5606969 March 4, 1997 Butler et al.
5607385 March 4, 1997 Francischelli et al.
5620466 April 15, 1997 Haefner et al.
5622178 April 22, 1997 Gilham
5626151 May 6, 1997 Linden
5632281 May 27, 1997 Rayburn
5634938 June 3, 1997 Swanson et al.
5641326 June 24, 1997 Adams
5645570 July 8, 1997 Corbucci
5658318 August 19, 1997 Stroetmann et al.
5662688 September 2, 1997 Haefner et al.
5690681 November 25, 1997 Geddes et al.
5693000 December 2, 1997 Crosby et al.
5697951 December 16, 1997 Harpstead et al.
5697953 December 16, 1997 Kroll et al.
5700282 December 23, 1997 Zabara
5701894 December 30, 1997 Cherry et al.
5704345 January 6, 1998 Berthon-Jones
5704365 January 6, 1998 Albrecht et al.
5707400 January 13, 1998 Terry, Jr. et al.
5713355 February 3, 1998 Richardson et al.
5713933 February 3, 1998 Condie et al.
5715812 February 10, 1998 Deighan et al.
5716377 February 10, 1998 Rise et al.
5720771 February 24, 1998 Snell
5724984 March 10, 1998 Arnold et al.
5740797 April 21, 1998 Dickson
5782883 July 21, 1998 Kroll et al.
5792188 August 11, 1998 Starkweather et al.
5794615 August 18, 1998 Estes
5797967 August 25, 1998 KenKnight
5800470 September 1, 1998 Stein et al.
5802188 September 1, 1998 McDonough
5814079 September 29, 1998 Kieval
5826579 October 27, 1998 Remmers et al.
5827326 October 27, 1998 Kroll et al.
5839430 November 24, 1998 Cama
5844680 December 1, 1998 Sperling
5860918 January 19, 1999 Schradi et al.
5861011 January 19, 1999 Stoop
5869970 February 9, 1999 Palm et al.
5876353 March 2, 1999 Riff
5891023 April 6, 1999 Lynn
5895414 April 20, 1999 Sanchez-Zambrano
5902250 May 11, 1999 Verrier et al.
5911218 June 15, 1999 DiMarco
5916239 June 29, 1999 Geddes et al.
5919141 July 6, 1999 Money et al.
5957861 September 28, 1999 Combs et al.
5957956 September 28, 1999 Kroll et al.
5961446 October 5, 1999 Beller et al.
5961450 October 5, 1999 Merchant et al.
5964788 October 12, 1999 Greenhut
5970975 October 26, 1999 Estes et al.
5974340 October 26, 1999 Kadhiresan
5974349 October 26, 1999 Levine
5981011 November 9, 1999 Overcash et al.
5997526 December 7, 1999 Giba et al.
6006134 December 21, 1999 Hill et al.
6015388 January 18, 2000 Sackner et al.
6021351 February 1, 2000 Kadhiresan et al.
6044297 March 28, 2000 Sheldon et al.
6045513 April 4, 2000 Stone et al.
6047203 April 4, 2000 Sackner et al.
6050940 April 18, 2000 Braun et al.
6058331 May 2, 2000 King
6059725 May 9, 2000 Steinschneider
6064910 May 16, 2000 Andersson et al.
6073048 June 6, 2000 Kieval et al.
6091986 July 18, 2000 Keimel
6099479 August 8, 2000 Christopherson et al.
6105575 August 22, 2000 Estes et al.
6115628 September 5, 2000 Stadler et al.
6117092 September 12, 2000 Weinstein et al.
6120441 September 19, 2000 Griebel
6134470 October 17, 2000 Hartlaub
6141590 October 31, 2000 Renirie et al.
6144866 November 7, 2000 Miesel et al.
6148230 November 14, 2000 KenKnight
6148233 November 14, 2000 Owen et al.
6148814 November 21, 2000 Clemmer et al.
6155976 December 5, 2000 Sackner et al.
6161042 December 12, 2000 Hartley et al.
6168568 January 2, 2001 Gavriely
6178349 January 23, 2001 Kieval
6181961 January 30, 2001 Prass
6181966 January 30, 2001 Nigam
6200265 March 13, 2001 Walsh et al.
6205357 March 20, 2001 Ideker et al.
6212435 April 3, 2001 Lattner et al.
6227072 May 8, 2001 Ritchey et al.
6236873 May 22, 2001 Holmström
6240314 May 29, 2001 Plicchi et al.
6240316 May 29, 2001 Richmond et al.
6253103 June 26, 2001 Baura
6261238 July 17, 2001 Gavriely
6263244 July 17, 2001 Mann et al.
6264606 July 24, 2001 Ekwall et al.
6269269 July 31, 2001 Ottenhoff et al.
6270457 August 7, 2001 Bardy
6275727 August 14, 2001 Hopper et al.
6280462 August 28, 2001 Hauser et al.
6286508 September 11, 2001 Remmers et al.
6287264 September 11, 2001 Hoffman
6292693 September 18, 2001 Darvish et al.
6299581 October 9, 2001 Rapoport et al.
6303270 October 16, 2001 Flaim et al.
6306088 October 23, 2001 Krausman et al.
6310085 October 30, 2001 Willis
6312378 November 6, 2001 Bardy
6314319 November 6, 2001 Kroll et al.
6317627 November 13, 2001 Ennen
6327499 December 4, 2001 Alt
6331536 December 18, 2001 Radulovacki et al.
6336903 January 8, 2002 Bardy
6351670 February 26, 2002 Kroll
6357444 March 19, 2002 Parker
6360127 March 19, 2002 Ding et al.
6361494 March 26, 2002 Lindenthaler
6361522 March 26, 2002 Scheiner et al.
6366813 April 2, 2002 DiLorenzo
6375614 April 23, 2002 Braun et al.
6375623 April 23, 2002 Gavriely
6387907 May 14, 2002 Hendricks et al.
6397845 June 4, 2002 Burton
6398727 June 4, 2002 Bui et al.
6398728 June 4, 2002 Bardy
6398739 June 4, 2002 Sullivan et al.
6400982 June 4, 2002 Sweeney et al.
6409675 June 25, 2002 Turcott
6409676 June 25, 2002 Ruton
6411845 June 25, 2002 Mower et al.
6411850 June 25, 2002 Kay et al.
6414183 July 2, 2002 Sakamoto et al.
6415174 July 2, 2002 Bebehani et al.
6415183 July 2, 2002 Scheiner et al.
6421557 July 16, 2002 Meyer
6430439 August 6, 2002 Wentkowski et al.
6431171 August 13, 2002 Burton
6438407 August 20, 2002 Ousdigian et al.
6442413 August 27, 2002 Silver
6442433 August 27, 2002 Linberg
6447459 September 10, 2002 Larom
6449503 September 10, 2002 Hsu
6449507 September 10, 2002 Hill et al.
6450957 September 17, 2002 Yoshimi
6454708 September 24, 2002 Ferguson et al.
6454719 September 24, 2002 Greenhut
6463326 October 8, 2002 Hartley et al.
6467333 October 22, 2002 Lewis et al.
6468219 October 22, 2002 Njemanze
6473644 October 29, 2002 Terry, Jr. et al.
6477420 November 5, 2002 Struble et al.
6487450 November 26, 2002 Chen et al.
6491639 December 10, 2002 Turcott
6491675 December 10, 2002 Shimada et al.
6493585 December 10, 2002 Plicchi et al.
6496715 December 17, 2002 Lee et al.
6497658 December 24, 2002 Roizen et al.
6505067 January 7, 2003 Lee et al.
6511500 January 28, 2003 Rahme
6512940 January 28, 2003 Brabec et al.
6514218 February 4, 2003 Yamamoto
6522915 February 18, 2003 Ceballos et al.
6522926 February 18, 2003 Kieval et al.
6527729 March 4, 2003 Turcott
6532388 March 11, 2003 Hill et al.
6542774 April 1, 2003 Hill et al.
6544199 April 8, 2003 Morris
6547743 April 15, 2003 Brydon
6564096 May 13, 2003 Mest
6564106 May 13, 2003 Guck et al.
6572543 June 3, 2003 Christopherson et al.
6580944 June 17, 2003 Katz et al.
6584351 June 24, 2003 Ekwall
6595927 July 22, 2003 Pitts-Crick
6595928 July 22, 2003 Mansy et al.
6600949 July 29, 2003 Turcott
6606993 August 19, 2003 Wiesmann et al.
6607509 August 19, 2003 Bobroff et al.
6611713 August 26, 2003 Schauerte
6615083 September 2, 2003 Kupper
6618618 September 9, 2003 Kalgren et al.
6622041 September 16, 2003 Terry, Jr. et al.
6622046 September 16, 2003 Fraley et al.
6628986 September 30, 2003 Mouchawar et al.
6628987 September 30, 2003 Hill et al.
6641542 November 4, 2003 Cho et al.
6648833 November 18, 2003 Hampton
6658292 December 2, 2003 Kroll et al.
6662032 December 9, 2003 Gavish et al.
6679250 January 20, 2004 Walker et al.
6690971 February 10, 2004 Schauerte et al.
6694186 February 17, 2004 Bardy
6704590 March 9, 2004 Haldeman
6708058 March 16, 2004 Kim et al.
6723055 April 20, 2004 Hoffman
6731984 May 4, 2004 Cho et al.
6741885 May 25, 2004 Park et al.
6748252 June 8, 2004 Lynn et al.
6752765 June 22, 2004 Jensen et al.
6752766 June 22, 2004 Kowallik et al.
6754528 June 22, 2004 Bardy
6760615 July 6, 2004 Ferek-Petric
6766190 July 20, 2004 Ferek-Petric
6770022 August 3, 2004 Mechlenburg et al.
6770029 August 3, 2004 Iliff
6773404 August 10, 2004 Poezevera et al.
6778860 August 17, 2004 Ostroff
6786866 September 7, 2004 Odagiri et al.
6788974 September 7, 2004 Bardy et al.
6799072 September 28, 2004 Ries et al.
6810287 October 26, 2004 Zhu et al.
6811538 November 2, 2004 Westbrook et al.
6830548 December 14, 2004 Bonnet et al.
6834204 December 21, 2004 Ostroff
6850801 February 1, 2005 Kieval et al.
6856835 February 15, 2005 Bardy et al.
6857428 February 22, 2005 Thomton
6865417 March 8, 2005 Rissmann et al.
6866044 March 15, 2005 Bardy et al.
6890305 May 10, 2005 Irie et al.
6890306 May 10, 2005 Poezevera
6892095 May 10, 2005 Salo
6904320 June 7, 2005 Park et al.
6910481 June 28, 2005 Kimmel et al.
6912419 June 28, 2005 Hill et al.
6922589 July 26, 2005 Stahmann et al.
6927721 August 9, 2005 Ostroff
6928324 August 9, 2005 Park et al.
6934583 August 23, 2005 Weinberg et al.
6937907 August 30, 2005 Bardy et al.
6950705 September 27, 2005 Bardy et al.
6951539 October 4, 2005 Bardy
6952608 October 4, 2005 Ostroff
6952610 October 4, 2005 Ostroff et al.
6954670 October 11, 2005 Ostroff
6959214 October 25, 2005 Pape et al.
6961619 November 1, 2005 Casey
6964641 November 15, 2005 Cho et al.
6988003 January 17, 2006 Bardy et al.
6988498 January 24, 2006 Berthon-Jones et al.
6993389 January 31, 2006 Ding et al.
6999817 February 14, 2006 Park et al.
7025729 April 11, 2006 de Chazal et al.
7025730 April 11, 2006 Cho et al.
7027861 April 11, 2006 Thompson
7027871 April 11, 2006 Burnes
7039459 May 2, 2006 Bardy et al.
7039465 May 2, 2006 Bardy et al.
7039468 May 2, 2006 Freed et al.
7043299 May 9, 2006 Erlinger et al.
7062308 June 13, 2006 Jackson
7065407 June 20, 2006 Bardy et al.
7065410 June 20, 2006 Bardy et al.
7069080 June 27, 2006 Bardy et al.
7076296 July 11, 2006 Rissmann et al.
7081095 July 25, 2006 Lynn et al.
7089936 August 15, 2006 Madaus et al.
7090682 August 15, 2006 Sanders et al.
7092754 August 15, 2006 Bardy et al.
7092755 August 15, 2006 Florio
7094207 August 22, 2006 Koh
7110820 September 19, 2006 Tcheng et al.
7115097 October 3, 2006 Johnson
7117036 October 3, 2006 Florio
7120495 October 10, 2006 Bardy et al.
7127290 October 24, 2006 Girouard
7130687 October 31, 2006 Cho et al.
7136704 November 14, 2006 Schulman
7146212 December 5, 2006 Bardy et al.
7149574 December 12, 2006 Yun et al.
7149575 December 12, 2006 Ostroff et al.
7155278 December 26, 2006 King
7179229 February 20, 2007 Koh
7184817 February 27, 2007 Zhu et al.
7189204 March 13, 2007 Ni et al.
7194302 March 20, 2007 Bardy
7194309 March 20, 2007 Ostroff et al.
7194313 March 20, 2007 Libbus
7204805 April 17, 2007 Dean
7207945 April 24, 2007 Bardy
7212862 May 1, 2007 Park et al
7218964 May 15, 2007 Hill et al.
7225013 May 29, 2007 Geva et al.
7225021 May 29, 2007 Park et al.
7225809 June 5, 2007 Bowen et al.
7231250 June 12, 2007 Band et al.
7252640 August 7, 2007 Ni et al.
7269459 September 11, 2007 Koh
7277757 October 2, 2007 Casavant et al.
7289854 October 30, 2007 Bardy et al.
7292890 November 6, 2007 Whitehurst
7302295 November 27, 2007 Stahmann et al.
7308311 December 11, 2007 Sorensen
7395115 July 1, 2008 Poezevera
7396333 July 8, 2008 Stahmann et al.
7400928 July 15, 2008 Hatlestsad
7428468 September 23, 2008 Takemura et al.
7438686 October 21, 2008 Cho et al.
7440795 October 21, 2008 Poezevara
7445601 November 4, 2008 Kline
7460906 December 2, 2008 Libbus
7469697 December 30, 2008 Lee et al.
7481759 January 27, 2009 Whitehurst et al.
7486991 February 3, 2009 Libbus et al.
7499750 March 3, 2009 Haefner
7509166 March 24, 2009 Libbus
7515969 April 7, 2009 Tockman
7570997 August 4, 2009 Lovett et al.
7662101 February 16, 2010 Lee et al.
7664546 February 16, 2010 Hartley et al.
7678061 March 16, 2010 Lee et al.
7680537 March 16, 2010 Stahmann et al.
7720541 May 18, 2010 Stahmann et al.
7747323 June 29, 2010 Libbus et al.
7757690 July 20, 2010 Stahmann et al.
7766842 August 3, 2010 Ni et al.
7869881 January 11, 2011 Libbus
7887493 February 15, 2011 Stahmann et al.
8002553 August 23, 2011 Hatlestad
20020002327 January 3, 2002 Grant et al.
20020035377 March 21, 2002 Bardy et al.
20020035378 March 21, 2002 Bardy et al.
20020035379 March 21, 2002 Bardy et al.
20020035381 March 21, 2002 Bardy et al.
20020058877 May 16, 2002 Baumann et al.
20020072776 June 13, 2002 Osorio et al.
20020082658 June 27, 2002 Heinrich et al.
20020085741 July 4, 2002 Shimizu
20020095184 July 18, 2002 Bardy et al.
20020107544 August 8, 2002 Ostroff et al.
20020107545 August 8, 2002 Rissmann et al.
20020107553 August 8, 2002 Hill et al.
20020120304 August 29, 2002 Mest
20020136328 September 26, 2002 Shimizu
20020138563 September 26, 2002 Trivedi
20020143369 October 3, 2002 Hill et al.
20020161410 October 31, 2002 Kramer et al.
20020165586 November 7, 2002 Hill et al.
20020169485 November 14, 2002 Pless et al.
20020183237 December 5, 2002 Puskas
20020193685 December 19, 2002 Mate et al.
20020198570 December 26, 2002 Puskas
20030003052 January 2, 2003 Hampton
20030004549 January 2, 2003 Hill et al.
20030004552 January 2, 2003 Plombon et al.
20030023175 January 30, 2003 Arzbaecher et al.
20030023279 January 30, 2003 Spinelli et al.
20030036773 February 20, 2003 Whitehurst et al.
20030045909 March 6, 2003 Gross et al.
20030045914 March 6, 2003 Cohen et al.
20030050538 March 13, 2003 Naghavi et al.
20030060857 March 27, 2003 Perrson et al.
20030060858 March 27, 2003 Kieval et al.
20030074039 April 17, 2003 Puskas
20030078623 April 24, 2003 Weinberg et al.
20030078629 April 24, 2003 Chen
20030083241 May 1, 2003 Young
20030083587 May 1, 2003 Ferek-Petric
20030088027 May 8, 2003 Chin et al.
20030100924 May 29, 2003 Foreman et al.
20030105493 June 5, 2003 Salo
20030105497 June 5, 2003 Zhu et al.
20030121519 July 3, 2003 Estes et al.
20030139780 July 24, 2003 Markowitz et al.
20030149450 August 7, 2003 Mayberg
20030149457 August 7, 2003 Tcheng et al.
20030178031 September 25, 2003 Du Pen et al.
20030181951 September 25, 2003 Cates
20030195578 October 16, 2003 Perron et al.
20030204146 October 30, 2003 Carlson
20030209246 November 13, 2003 Schroeder et al.
20030212436 November 13, 2003 Brown
20030212440 November 13, 2003 Boveja
20030216789 November 20, 2003 Deem et al.
20030216792 November 20, 2003 Levin et al.
20030236558 December 25, 2003 Whitehurst et al.
20040010303 January 15, 2004 Bolea
20040019364 January 29, 2004 Kieval et al.
20040059240 March 25, 2004 Cho et al.
20040073093 April 15, 2004 Hatlestad
20040073128 April 15, 2004 Hatlestad
20040111021 June 10, 2004 Olson
20040111040 June 10, 2004 Ni et al.
20040111041 June 10, 2004 Ni et al.
20040116981 June 17, 2004 Mazar
20040122487 June 24, 2004 Hatlestad et al.
20040122488 June 24, 2004 Mazar et al.
20040128161 July 1, 2004 Mazar et al.
20040133079 July 8, 2004 Mazar et al.
20040134496 July 15, 2004 Cho et al.
20040163648 August 26, 2004 Burton
20040172074 September 2, 2004 Yoshihito
20040176809 September 9, 2004 Cho et al.
20040193231 September 30, 2004 David et al.
20040199210 October 7, 2004 Shelchuk
20040215240 October 28, 2004 Lovett et al.
20040215289 October 28, 2004 Fukui
20040230229 November 18, 2004 Lovett et al.
20040230230 November 18, 2004 Lindstrom
20040243012 December 2, 2004 Ciaccio et al.
20040254616 December 16, 2004 Rossing et al.
20050004615 January 6, 2005 Sanders
20050039745 February 24, 2005 Stahmann et al.
20050043644 February 24, 2005 Stahmann et al.
20050043652 February 24, 2005 Lovett et al.
20050043772 February 24, 2005 Stahmann et al.
20050061319 March 24, 2005 Hartley et al.
20050065572 March 24, 2005 Hartley et al.
20050065575 March 24, 2005 Dobak
20050069322 March 31, 2005 Tegge, Jr. et al.
20050085864 April 21, 2005 Schulman et al.
20050085865 April 21, 2005 Tehrani
20050096705 May 5, 2005 Pastore et al.
20050101841 May 12, 2005 Kaylor et al.
20050107838 May 19, 2005 Lovett et al.
20050113710 May 26, 2005 Stahmann et al.
20050131467 June 16, 2005 Boveja
20050137645 June 23, 2005 Voipio et al.
20050142070 June 30, 2005 Hartley et al.
20050143779 June 30, 2005 Libbus
20050143785 June 30, 2005 Libbus
20050143787 June 30, 2005 Boveja et al.
20050149126 July 7, 2005 Libbus
20050149127 July 7, 2005 Libbus
20050149128 July 7, 2005 Heil, Jr. et al.
20050149129 July 7, 2005 Libbus et al.
20050149131 July 7, 2005 Libbus et al.
20050149132 July 7, 2005 Libbus
20050149133 July 7, 2005 Libbus et al.
20050149155 July 7, 2005 Scheiner et al.
20050149156 July 7, 2005 Libbus et al.
20050159784 July 21, 2005 Arceta
20050165323 July 28, 2005 Montgomery et al.
20050197675 September 8, 2005 David et al.
20050240240 October 27, 2005 Park et al.
20060079945 April 13, 2006 Libbus
20060106428 May 18, 2006 Libbus et al.
20060106429 May 18, 2006 Libbus et al.
20060116737 June 1, 2006 Libbus
20060122675 June 8, 2006 Libbus et al.
20060206153 September 14, 2006 Libbus
20060206154 September 14, 2006 Moffitt
20060217772 September 28, 2006 Libbus
20060224188 October 5, 2006 Libbus et al.
20060293714 December 28, 2006 Salo et al.
20070005114 January 4, 2007 Salo et al.
20070093875 April 26, 2007 Chavan et al.
20070112388 May 17, 2007 Salo
20070142741 June 21, 2007 Berthon-Jones et al.
20070142871 June 21, 2007 Libbus et al.
20070150014 June 28, 2007 Kramer et al.
20070161873 July 12, 2007 Ni et al.
20070239057 October 11, 2007 Pu et al.
20070282215 December 6, 2007 Ni et al.
20110137197 June 9, 2011 Stahmann et al.
Foreign Patent Documents
0547734 June 1993 EP
0750920 January 1997 EP
0770407 May 1997 EP
1038498 September 2000 EP
1162125 December 2001 EP
1172125 January 2002 EP
1234597 August 2002 EP
1304137 April 2003 EP
1317943 June 2003 EP
1486232 December 2004 EP
1541193 June 2005 EP
WO8402080 July 1984 WO
WO8605965 October 1986 WO
WO9203983 March 1992 WO
WO9220402 November 1992 WO
WO9301862 February 1993 WO
WO9904841 April 1999 WO
WO0009206 February 2000 WO
WO0017615 March 2000 WO
WO0124876 April 2001 WO
WO0143804 June 2001 WO
WO0176689 October 2001 WO
WO0226318 April 2002 WO
WO0234327 May 2002 WO
WO02075744 September 2002 WO
WO02085448 October 2002 WO
WO03003905 January 2003 WO
WO03011388 February 2003 WO
WO03041559 May 2003 WO
WO03075744 September 2003 WO
WO03076008 September 2003 WO
WO03082080 October 2003 WO
WO03099373 December 2003 WO
WO03099377 December 2003 WO
WO2004012814 February 2004 WO
WO2004062485 July 2004 WO
WO2004084990 October 2004 WO
WO2004084993 October 2004 WO
WO2004103455 December 2004 WO
WO2004105870 December 2004 WO
WO2004110549 December 2004 WO
WO2005018739 March 2005 WO
WO2005028029 March 2005 WO
WO2005042091 May 2005 WO
WO2005053788 June 2005 WO
WO 05063332 July 2005 WO
WO2005065771 July 2005 WO
WO2006031331 March 2006 WO
Other references
  • File History for U.S. Appl. No. 10/939,834.
  • File History for U.S. Appl. No. 10/939,811.
  • File History for U.S. Appl. No. 10/642,998.
  • Roche et al., Screening of Obstructive Sleep Apnea Syndrome by Heart Rate Variability Analysis, 100 Circulation 1411-1455 (1999).
  • Smits et al., Defibrillation Threshold (DFT) Model of a Fully Subcutaneous ICD System, Europace Supplements, vol. 2, Jun. 2001 at col. 778, p. B83.
  • Steltner et al., Diagnosis of Sleep Apnea by Automatic Analysis of Nasal Pressure and Forced Oscillation Impedance. Am. Journal Respiratory Critical Care Medicine, vol. 165, pp. 940-944 (2002).
  • Stirbis et al., Optimizing the Shape of Implanted Artificial Pacemakers, Kaunas Medical Institute. Translated from Meditsinskaya Tekhnika, No. 6, pp. 25-27, 1986.
  • Vanninen et al., Cardiac Sympathovagal Balance During Sleep Apnea Episodes, 16 Clin. Physiol. 209-216 (1996).
  • Waldemark et al., Detection of Apnea using Short Window FFT Technique and Artificial Neural Network, 3390 SPIE International Society for Optical Engineering 122-133 (1998).
  • Young et al., The Occurrence of Sleep-disordered Breathing Among Middle-aged Adults, The New England Journal of Medicine, vol. 828, No. 17, pp. 1230-1235.
  • Aircraft Noise and Sleep Disturbance: Final Report, prepared by the Civil Aviation Authority London on behalf of the Department of Trade, Aug. 1980 (CAA Report).
  • Alijore et al., Nightcap: Laboratory and home-based evaluation of a portable sleep monitor, 32 Psychophysiology, 32-98 (1995). Abstract only.
  • Altshule et al., The Effect of Position on Periodic Breathing in Chronic Cardiac Decomposition, New Eng. Journal of Med., vol. 259, No. 22, pp. 1064-1066, Nov. 27, 1958.
  • Andersen, Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome, Lancet, 350(9086), Oct. 25, 1997, 1210-6.
  • Balaban et al., Feasibility of Screening for Sleep Apnea Using Pacemaker Impedance Sensor, NASPE (2001).
  • Baratz et al., Effect of Nasal Continuous Positive Airway Pressure on Cardiac Output and Oxygen Delivery in Patients With Congestive Heart Failure, 102 Chest, 1992, 397-401.
  • Benchimol, Cardiac hemodynamics during stimulation of the right atrium, right ventricle, and left ventricle in normal and abnormal hearts, Circulation, 33(6), Jun. 1966, 933-44.
  • Bevan et al., Sympathetic nerve-free vascular muscle, Journal of Pharmacology & Experimental Therapeutics, 157(1), Jul. 1967, 117-24.
  • Bevan et al., Postganglionic sympathetic delay in vascular smooth muscle, Journal of Pharmacology & Experimental Therapeutics, 152(2), May 1966, 211-30.
  • Bilgutay et al., Vagal tuning for the control of supraventricular arrhythmias, Surgical Forum, 16, 1965, 151-3.
  • Bilgutay et al. A new concept in the treatment of hypertension utilizing an implantable electronical device: Baropacer. Trans. Am. Society Artificial Internal Organs. 1964. vol. 10, pp. 387-395.
  • Borst et al., Optimal frequency of carotid sinus nerve stimulation in treatment of angina pectoris, Cardiovascular Research, 8(5), Sep. 1974, 674-80.
  • Bradley et al, Cardiac Output Response to Continuous Positive Airway Pressure in Congestive Heart Failure, 145 Am. Rev. Respir. Dis. 377-382 (1992).
  • Bradley et al., Sleep Apnea and Heart Failure, Part I: Obstructive Sleep Apnea, 107 Circulation 1671-1678 (2003).
  • Bradley et al., Pathophysiologic and Therapeutic Implications of Sleep Apnea in Congestive Heart Failure, 3 J. Cardiac Failure 223-240 (1996).
  • Braunwald et al., Carotid sinus nerve stimulation in the treatment of angina pectoris and supraventricular trachycardia, California Medicine, 112(3), Mar. 1970, 41-50.
  • Braunwald et al., Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves, New England Journal of Medicine, 277(24), Dec. 14, 1967, 1278-83.
  • Buda et al., Effect of Intrathoracic Pressure on Left Ventricular Performance, 301 Engl. J. Med. 453-459 (1979).
  • Calvin et al., Positive End-Expiratory Pressure (PEEP) Does Not Depress Left Ventricular Function in Patients With Pulmonary Edema, 124 Am. Rev. Respir. Dis. 121-128 (1981).
  • Chapleau, Contrasting effects of static and pulsatile pressure on carotid baroreceptor activity in dogs, Circulation, vol. 61, No. 5, Nov. 1987, pp. 648-658.
  • Coleridge et al. “The distribution, connexions and histology of baroreceptors in the pulmonary artery, with some observations on the sensory innervation of the ductus arteriosus.” Physiology. May 1961. vol. 156, pp. 591-602.
  • Cooper et al., Neural effects on sinus rate and atrioventricular conduction produced by electrical stimulation from a transvenous electrode catheter in the canine right pulmonary artery, Circulation Research, 46(1), Jan. 1980, 48-57.
  • Dark et al., Breathing Pattern Abnormalities and Arterial Oxygen Desaturation During Sleep in the Congestive Heart Failure Syndrome, Chest, Jun. 1987, 6:833-6.
  • Dart Jr. et al., Carotid sinus nerve stimulation treatment of angina refractory to other surgical procedures, Annals of Thoracic Surgery, 11(4), Apr. 1971, 348-59.
  • De Hoyos et al., Haemodynamic Effects of Continuous Positive Airway Pressure in Humans With Normal and Impaired Left Ventricular Function, 88 Clin. Sci. (Lond). 173-8 (1995).
  • De Landsheere et al., Effect of spinal cord stimulation on regional myocardial perfusion assessed by positron emission tomography, American Journal of Cardiology, 69(14), May 1, 1992, 1143-9.
  • Dunning, Electrostimulation of the Carotid Sinus Nerve in Angina Pectoris, University Department of Medicine, Binnengasthuis, Amsterdam: Printed by Royal VanGorcum, Assen, Netherlands, 1971, 1-92.
  • Farrehi, Stimulation of the carotid sinus nerve in treatment of angina pectoris, American Heart Journal, 80(6), Dec. 1970, 759-65.
  • Feliciano et al., Vagal nerve stimulation releases vasoactive intestinal peptide which significantly increases coronary artery blood flow, Cardiovascular Research, 40(1), Oct. 1998, 45-55.
  • Fromer et al., Ultrarapid subthreshold stimulation for termination of atrioventricular node reentrant tachycardia, Journal of the American College of Cardiology, 20(4), Oct. 1992, 879-83.
  • Garrigue, Night Atrial Overdrive with DDD Pacing Results in a Significant Reduction of Sleep Apnea Episodes and QOL Improvement in Heart Failure Patients, Hosp. Cardiologique du Haut-Leveque, Bordeaux-Pessac, France, Abstract Session 25, p. 145.
  • Garrigue et al., Night Atrial Overdrive with DDD Pacing: a New Therapy for Sleep Apnea Syndrome, NASPE (2000).
  • Garrigue et al., Benefit of Atrial Pacing in Sleep Apnea Syndrome, 346 N. Engl. J. Med. 404-412 (2002).
  • Giardino et al., Respiratory Sinus Arrhythmia is Associated with the Efficiency of Pulmonary Gas Exchange in Healthy Humans, 284 Am. J. Physiol. H1585-1591 (2003).
  • Gradaus et al., Nonthoracotomy Implantable Cardioverter Defibrillator Placement in Children: Use of a Subcutaneous Array Leads and Abdominally Placed Implantable Cardioverter Defibrillators in Children, J. of Cardiovascular Electrophysiology, vol. 12, No. 3, pp. 356-360 (Mar. 2001).
  • Grassi et al., Baroreflex and non-baroreflex modulation of vagal cardiac control after myocardial infarction, Am J Cardiol, 84(5), Sep. 1, 1999, 525-9.
  • Griffith et al., Electrical Stimulation of the Carotid Sinus Nerve in Normotensive and Renal Hypertensive Dogs, Circulation, Jul.-Dec. 28, 1963, 730.
  • Hanson et al., Cardiac Gated Ventilation, 2433 SPIE 303-308 (1995).
  • Hartz et al., New Approach to Defibrillator Insertion, J. Thoracic Cardiovascular Surgery, vol. 97, pp. 920-922 (1989).
  • Henning, Effects of autonomic nerve stimulation, asynchrony, and load on dP/dtmax and on dP/dtmin, American Journal of Physiology, 260(4PT2), Apr. 1991, H1290-8.
  • Henning et al., Vagal nerve stimulation increases right ventricular contraction and relaxation and heart rate, Cardiovascular Research, 32(5), Nov. 1996, 846-53.
  • Hilton et al., Evaluation of Frequency and Time-frequency Spectral Analysis of Heart Rate Variability as a Diagnostic Marker of the Sleep Apnea Syndrome. Med Biol Eng Comput Nov. 1999, 37(6), 760-9.
  • Hoffman et al., Cheyne-Stokes Respiration in Patients Recovering from Acute Cardiogenic Pulmonary Edema, Chest 1990, 97:410-12.
  • Hood Jr. et al., Asynchronous contraction due to late systolic bulging at left ventricular pacing sites, American Journal of Physiology, 217(1), Jul. 1969, 215-21.
  • Ishise, Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure, Journal of Applied Physiology 84(4), Apr. 1998, 1234-41.
  • Janes, Anatomy of human extrinsic cardiac nerves and ganglia, Am J Cardiol., 57(4), Feb. 1, 1986, 299-309.
  • Javaheri et al., “Sleep Apnea in 81 Ambulatory Male Patients with Stable Heart Failure”, from the Sleep Disorders Laboratory, Department of Veterans Affairs Medical Center, and the Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, pp. 2154-2159.
  • Jessurun et al., Coronary blood flow dynamics during transcutaneous electrical nerve stimulation for stable angina pectoris associated with severe narrowing of one major coronary artery, American Journal of Cardiology, 82(8), erratum appears in Am J Cardiol, Feb. 1999, 15;83(4):642, Oct. 15, 1998, 921-6.
  • Junyu et al., Posture Detection Algorithm Using Multi Axis DC-Accelerometer, Pace vol. 22, Apr. 1999.
  • Kandel et al., Part VII: Arousal, Emotion, and Behavioral Homeostasis, In: Principles of neural science, New York:McGraw-Hill, Health Professions Division, 2000, 966-969.
  • Karpawich et al., Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block, Pacing Clin Electrophysiol, 22(9), Sep. 1999, 1372-7.
  • Kaye et al., Acute Effects of Continuous Positive Airway Pressure on Cardiac Sympathetic Tone in Congestive Heart Failure, 103 Circulation 2336-24338 (2001).
  • Kolettis et al., Submammary Implantation of a Cardioverter-Defibrillator with a Nonthoractomy Lead System, Am. Heart J., vol. 126, pp. 1222-1223 (Nov. 1993).
  • Krahn et al. Recurrent syncope. Experience with an implantable loop record. Cardiol. Clin., vol. 15(2), May 1997, pp. 316-326.
  • Laude et al., Effects of Breathing Pattern on Blood Pressure and Heart Rate Oscillations in Humans, 20 Clin. Exp. Pharmol. Phisiol 619, 625 (1993).
  • Leclercq et al., Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing, Am Heart J., 129(6), Jun. 1995, 1133-41.
  • Leng et al., Lead Configuration for Defibrillator Implantation in a Patient with Congenital Heart Disease and a Mechanical Prosthetic Tricuspid Valve, PACE, vol. 24, pp. 1291-1292, Aug. 2001.
  • Lenique et al., Ventilatory and Hemodynamic Effects of Continuous Positive Airway Pressure in Left Heart Failure, 155 Am. J. Respir. Crit. Care Med. 500-505 (1997).
  • Li, Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats, Circulation, 109(1), Epub Dec. 8, 2003, Jan. 6, 2004, 1-5.
  • Lugaresi et al., Snoring, 39 Electroencephalogr. Clin. Neurophysiol. 59-64 (1975).
  • Mannheimer et al., Epidural spinal electrical stimulation in severe angina pectoris, British Heart Journal, 59(1), Jan. 1988, 56-61, Abstract only.
  • Mannheimer et al., Transcutaneous electrical nerve stimulation in severe angina pectoris, European Heart Journal, 3(4), Aug. 1982, 297-302, Abstract only.
  • Mansfield, D. et al., Effects of Continuous Positive Airway Pressure on Lung Function in Patients with Chronic Obstructive Pulmonary Disease and Sleep Disordered Breathing, Respirology 365-70 (1999). Abstract only.
  • Mazgalev et al., Autonomic modification of the atrioventricular node during atrial fibrillation: role in the slowing of ventricular rate, Circulation 99(21), Jun. 1, 1999, 2806-14.
  • Millar-Craig et al., Circadian variation of blood-pressure, Lancet, 1(8068), Apr. 15, 1978, 795-7, Abstract only.
  • Minisi et al., Regional left ventricular deafferentation increases baroreflex sensitivity following myocardial infarction, Cardiovasc Res., 58(1), Apr. 1, 2003, 136-41.
  • Murphy et al., Intractable angina pectoris: management with dorsal column stimulation, Medical Journal of Australia, 146(5), Mar. 2, 1987, 260, Abstract only.
  • Neil et al. “Effects of electrical stimulation of the aortic nerve on blood pressure and respiration in cats and rabbits under chloralose and nembutal anaesthesia.” Journal of Physiology. Sep. 1949. vol. 109 (3-4) p. 392-401.
  • Park & Pollock, Use of an Implantable Cardioverter Defibrillator in an Eight-Month-Old Infant with Ventricular Fibrillation Arising from a Myocardial Fibroma, PACE, vol. 22, No. 1, pp. 138-139 Jan. 1999.
  • Peters et al., Tempral and spatial summation caused by aortic nerve stimulation in rabbits. Effects of stimulation frequencies and amplitudes. Journal of the Autonomic Nervous System. 1989. vol. 27, pp. 193-205.
  • Peters et al., The principle of electrical carotid sinus nerve stimulation: a nerve pacemaker system for angina pectoris and hypertension therapy, Annals of Biomedical Engineering, 8(4-6), 1980, 445-58.
  • Philbin et al., Inappropriate shocks delivered by an ICD as a result of sensed potentials from a transcutaneous electronic nerve stimulation unit, Pacing & Clinical Electrophysiology, 21(10), Oct. 1998, 2010-1.
  • Pinsky et al., Augmentation of Cardiac Function by Elevation of Intrathoracic Pressure, 54 J. Appl. Physiol., 1983, 950-955.
  • Pinsky et al., Hemodynamic Effect of Cardiac Cycle-Specific Increases in Intrathoracic Pressure, 6 J. Appl. Physiol. 604-612 (1986).
  • Potkin et al., Effect of positive end-expiratory pressure on right and left ventricular function in patients with the adult respiratory distress syndrome, 135 Am. Rev. Respir. Dis. 307-311 (1987).
  • Prakash et al. Asymmetrical distribution of aortic nerve fibers in the pig, Anat Rec., 158(1), May 1967, 51-7.
  • Rasanen et al., Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Respiratory Failure. The Effects of Continuous Positive Airway Pressure, 87 Chest, 1985, 158-62.
  • Reddel et al., Analysis of Adherence to Peak Flow Monitoring When Recording of Data is Electronic, BMJ 146-147 (2002).
  • Rees et al., Paroxysmal Nocturnal Dyspnoea and Periodic Respiration, The Lancet, Dec. 22-29, 1979, pp. 1315-1317.
  • Rosenqvist, The effect of ventricular activation sequence on cardiac performance during pacing, Pacing and Electro-physiology, 19(9), 1996, 1279-1286.
  • Rushmer, Chapter 5—Systemic Arterial Pressure, In: Cardiovascular dynamics, Philadelphia: Saunders, 1976, 176-216.
  • Sato et al. “Novel Therapeutic Strategy against Central Baroreflex Failure: A Bionic Baroreflex System.” Circulation. Jul. 1999 vol. 100, pp. 299-304.
  • Satoh et al., “Role of Hypoxic Drive in Regulation of Postapneic Ventilation During Sleep in Patients with Obstructive Sleep Apnea”, Am Rev Respir Dis, Mar. 1991 143 (3): 481-485.
  • Schauerte et al., Catheter stimulation of cardiac parasympathetic nerves in humans: a novel approach to the cardiac autonomic nervous system, Circulation, 104(20), Nov. 13, 2001, 2430-5.
  • Schauerte, Transvenous Parasympathetic Nerve Stimulation in the Inferior Vena Cava and Atrioventricular Conduction, Journal of Cardiovascular Electrophysiology, 11(1), Jan. 2000, 64-69.
  • Schauerte et al., Ventricular rate control during atrial fibrillation by cardiac parasympathetic nerve stimulation: a transvenous approach, Journal of the American College of Cariology, 34(7), Dec. 1999, 2043-50.
  • Scherlag, Endovascular Neural Stimulation via a Novel Basket Electrode Catheter: Comparison of Electrode Configurations, Journal of Interventional Cardiac Electrophysiology, 4(1), Apr. 2000, 219-224.
  • Schuder et al., Experimental Ventricular Defibrillation with an Automatic and Completely Implanted System, Trans. Am. Soc. Artif. Int. Organs, vol. 16, pp. 207-212 (1970).
  • Schuder et al., Transthoracic Ventricular Defibrillation in the Dog with Truncated and Untruncated Exponential Stimuli, IEEE Trans. On Bio-Medical Engin., vol. BME-18, No. 6, pp. 410-415 Nov. 1971.
  • Schuder et al., Ventricular Defibrillation in the Dog Using Implanted and Partially Implanted Electrode Systems, Am. J. of Cardiology, vol. 33, pp. 243-247 Feb. 1974.
  • Takahashi, Vagal modulation of ventricular tachyarrhythmias induced by left ansae subclaviae stimulation in rabbits, Japanese Heart Journal, 39(4), Jul. 1998, 503-11.
  • Thrasher et al. “Unloading arterial baroreceptors causes neurogenic hypertension.” American Journal Physiol. Regulatory Integrative Comp. Physiol. 2002. vol. 282, R1044-R1053.
  • Tkacova et al., Left Ventricular Volume in Patients with Heart Failure and Cheyne-Strokes Respiration during Sleep, Am. Journal, Respir. Crit. Care Med., vol. 156, pp. 1549-1555, 1997.
  • Tse et al., Long-term effect of right ventricular pacing on myocardial perfusion and function, J Am Coll Cardiol., 29(4), Mar. 15, 1997, 744-9.
  • Veerman et al., Circadian profile of systemic hemodynamics, Hypertension, 26(1), Jul. 1995, 55-9.
  • Verity et al., Plurivesicular nerve endings in the pulmonary artery, Nature, 211(48), Jul. 30, 1966, 537-8.
  • Verity et al., Pulmonary artery innvervation: a morphopharmacologic correlation, Proceedings of the Western Pharmacology Society, 8, 1965, 57-9.
  • Wallick, Selective AV nodal vagal stimulation improves hemodynamics during acute atrial fibrillation in dogs, American Journal of Physiology—Heart & Circulatory Physiology, 281(4), Oct. 2001, H1490-7.
  • Waninger et al., Electrophysiological control of ventricular rate during atrial fibrillation, Pacing & Clinical Electrophysiology, 23(8), Aug. 2000, 1239-44.
  • Weber et al., Effects of CPAP and BIPAP on stroke volume in patients with obstructive sleep apnea syndrome. Pneumolgie Mar. 1995;49(3):233-5.
  • Wiggers et al., The muscular reactions of the mammalian ventricles to artificial surface stimuli, American Journal of Physiology, 1925, 346-378.
  • Young et al., The Occurrence of Sleep-disordered Breathing Among Middle-aged Adults, The New England Journal of Medicine, vol. 328, No. 17, pp. 1230-1235.
  • Zarzoso et al., Noninvasive Fetal Electrocardiogram Extraction: Blind Separation Versus Adaptive Noise Cancellation, IEEE Transactions on Biomedical Engineering, vol. 48, No. 1, pp. 12-18, Jan. 2001.
  • Zhang et al., Optimal ventricular rate slowing during atrial fibrillation by feedback AV nodal-selective vagal stimulation, American Journal of Physiology—Heart & Circulatory Physiology, 282(3), Mar. 2002, H1102-10.
  • Zhou et al., Prevention of high incidence of neurally mediated ventricular arrhythmias by afferent nerve stimulation in dogs, Circulation, 101(7), Feb. 22, 2000, 819-24.
Patent History
Patent number: 8915741
Type: Grant
Filed: Aug 23, 2011
Date of Patent: Dec 23, 2014
Patent Publication Number: 20110306850
Assignee: Cardiac Pacemakers, Inc. (St. Paul, MN)
Inventors: John D. Hatlestad (Maplewood, MN), Quan Ni (Shoreview, MN), Jeffrey E. Stahmann (Ramsey, MN), Jesse Hartley (White Bear Lake, MN), Qingsheng Zhu (Wexford, PA), Bruce H. KenKnight (Maple Grove, MN), Douglas R. Daum (Woodbury, MN), Kent Lee (Shoreview, MN)
Primary Examiner: Timothy A Musselman
Application Number: 13/215,592
Classifications
Current U.S. Class: Anatomy, Physiology, Therapeutic Treatment, Or Surgery Relating To Human Being (434/262)
International Classification: G09B 23/28 (20060101); A61B 5/0205 (20060101); A61B 5/00 (20060101); A61B 5/0488 (20060101); A61B 5/11 (20060101); A61B 5/0476 (20060101); A61N 1/362 (20060101); A61B 5/08 (20060101); A61B 5/0496 (20060101);